Pharmacoeconomic study of active psoriatic arthritis treatment ; Фармакоэкономический анализ терапии активного псориатического артрита

Συγγραφείς: A. V. Rudakova, Т. V. Korotaeva, А. В. Рудакова, Т. В. Коротаева

Πηγή: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 17, No 4 (2024); 504-512 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 17, No 4 (2024); 504-512 ; 2070-4933 ; 2070-4909

Θεματικοί όροι: таргетные синтетические базисные противовоспалительные препараты, psoriatic arthritis, netakimab, biological disease-modifying antirheumatic drugs, targeted synthetic disease-modifying antirheumatic drugs, псориатический артрит, нетакимаб, генно-инженерные биологические препараты

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/1139/590; Псориаз артропатический. Псориатический артрит. Клинические рекомендации. 2024. URL: https://cr.minzdrav.gov.ru/view-cr/562_3 (дата обращения 25.11.2024).; Gladman D.D., Antoni C., Mease P., et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 (Suppl. 2): ii14–7. https://doi.org/10.1136/ard.2004.032482.; Толкачева Д.Г., Младов В.В., Соколова В.Д. Эффективность генно-инженерных биологических и таргетных синтетических препаратов, зарегистрированных в России для терапии взрослых пациентов с активным псориатическим артритом: систематический обзор и сетевой метаанализ. Медицинские технологии. Оценка и выбор. 2021; 2: 51–66. https://doi.org/10.17116/medtech20214302151.; Румянцева Е.И., Железнякова И.А., Плахотник О.С. и др. Основные изменения в модели оплаты медицинской помощи по клиникостатистическим группам в Российской Федерации в 2024 году. Медицинские технологии. Оценка и выбор. 2024; 2: 10–21. https://doi.org/10.17116/medtech20244602110.; Lu C., Wallace B.I., Waljee A.K., et al. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta analysis. Semin Arthritis Rheum. 2019; 49 (3): 381–8. https://doi.org/10.1016/j.semarthrit.2019.06.001.; Ruyssen-Witrand A., Perry R., Watkins C., et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020; 6 (1): e001117. https://doi.org/10.1136/rmdopen-2019-001117.; Рудакова А.В., Толкачева Д.Г., Соколова В.Д. Фармакоэкономические аспекты терапии псориатического артрита среднетяжелой и тяжелой степени. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (2): 116–23. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.095.; https://www.pharmacoeconomics.ru/jour/article/view/1139

Διαθεσιμότητα: https://www.pharmacoeconomics.ru/jour/article/view/1139
https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.291

Analysis of methotrexate use practice in patients with rheumatoid and psoriatic arthritis ; Анализ практики использования метотрексата у пациентов с ревматоидным и псориатическим артритом

Συγγραφείς: S. A. Doktorova, Yu. Yu. Grabovetskaya, A. V. Zuev, J. N. Aksenova-Sorokhtei, V. V. Rafalskiy, С. А. Докторова, Ю. Ю. Грабовецкая, А. В. Зуев, Ю. Н. Аксенова-Сорохтей, В. В. Рафальский

Συνεισφορές: The study was supported by funds provided through the Russian Federal Strategic Academic Leadership Program “Priority 2030” at Immanuel Kant Baltic Federal University (project No. 123102600004-1), Исследование было поддержано из средств программы стратегического академического лидерства «Приоритет 2030» ФГАОУ ВО «Балтийский федеральный университет им. Иммануила Канта» (научный проект № 123102600004-1)

Πηγή: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 18, No 1 (2025); 33-41 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 18, No 1 (2025); 33-41 ; 2070-4933 ; 2070-4909

Θεματικοί όροι: базисные противовоспалительные препараты, methotrexate, rheumatic diseases, pharmacoepidemiology, ATC/DDD methodology, disease-modifying antirheumatic drugs, метотрексат, ревматологические заболевания, фармакоэпидемиология, методология ATC/DDD

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/1080/605; Рачина С.А., Козлов Р.С., Белькова Ю.А. Фармакоэпидемиология: от теоретических основ к практическому применению. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2014; 7 (1): 33–9.; Bilgin E., Duran E., Bolek E.C., et al. AB0742 conventional synthetic DMARDs in psoriatic arthritis – changing practice in biologic era: real-life results from HURBIO-PsA registry. Ann Rheum Dis. 2020; 79 (Suppl. 1): 1667.1. https://doi.org/10.1136/annrheumdis-2020-eular.4735.; Anghel L.A. Utilization patterns of disease-modifying antirheumatic drugs (DMARDs) in patients with autoimmune rheumatic diseases. Farmacia. 2019; 67 (1): 184–92. https://doi.org/10.31925/farmacia.2019.1.25.; Чичасова Н.В., Лила А.М. Метотрексат в лечении ревматоидного артрита и псориатического артрита. Лечащий врач. 2020; 7: 42–51. https://doi.org/10.26295/OS.2020.12.42.002.; Насонов Е.Л., Амирджанова В.Н., Олюнин Ю.А. и др. Применение метотрексата при ревматоидном артрите. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2023; 61 (4): 435–49. https://doi.org/10.47360/1995-4484-2023-435-449.; Ng B., Chu A., Khan M.M. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. BMJ Open. 2013; 3 (4): e002468. https://doi.org/10.1136/bmjopen-2012-002468.; Fassmer A.M., Garbe E., Schmedt N. Frequency and trends of diseasemodifying antirheumatic drug (DMARD) use in Germany. Pharmacol Res Perspect. 2016; 4 (5): e00254. https://doi.org/10.1002/prp2.254.; Jin X.M., Lee J., Choi N.K., et al. Utilization patterns of diseasemodifying antirheumatic drugs in elderly rheumatoid arthritis patients. J Korean Med Sci. 2014; 29 (2): 210–6. https://doi.org/10.3346/jkms.2014.29.2.210.; Зиганшина Л.Е., Магсумова Д.Р., Кучаева А.В. и др. ATC/DDD-классификационная система в фармакоэпидемиологических исследованиях. Качественная клиническая практика. 2004; 1: 28–33.; Elseviers M., Wettermark B., Almarsdóttir A.B., et al. Drug utilization research: methods and applications. Wiley-Blackwell; 2016: 536 pp.; ATC/DDD Index. Norwegian Institute of Public Health WHO Collaborating Centre for Drug Statistics Methodology. Available at: https://atcddd.fhi.no/atc_ddd_index/?code=L04AX03&showdescription=yes (accessed 16.07.2024).; Guidelines for ATC classification and DDD assignment. Norwegian Institute of Public Health WHO Collaborating Centre for Drug Statistics Methodology. Available at: https://atcddd.fhi.no/atc_ddd_index_and_guidelines/guidelines/ (accessed 16.07.2024).; Территориальный орган Федеральной службы государственной статистики по Калининградской области. Население. URL: https://39.rosstat.gov.ru/population (дата обращения 16.07.2024).; Hollingworth S., Kairuz T. Measuring medicine use: applying ATC/ DDD methodology to real-world data. Pharmacy. 2021; 9 (1): 60. https://doi.org/10.3390/pharmacy9010060.; Almutairi K., Nossent J., Preen D., et al. POS0632 The longitudinal associations of methotrexate and biologic use on hospital admission for rheumatoid arthritis patients in Western Australia population (1995– 2014). Ann Rheum Dis. 2021; 80 (Suppl. 1): 554. https://doi.org/10.1136/annrheumdis-2021-eular.3230.; Won S., Cho S.K., Kim D., et al. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization. Rheumatol Int. 2018; 38 (4): 649–56. https://doi.org/10.1007/s00296-017-3925-9.; Khraishi M., Ivanovic J., Zhang Y., et al. Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study. Curr Med Res Opin. 2019; 35 (11): 2025–33. https://doi.org/10.1080/03007995.2019.1636543.; Lee M.P., Lii J., Jin Y., et al. Patterns of systemic treatment for psoriatic arthritis in the US: 2004–2015. Arthritis Care Res. 2018; 70 (5): 791–6. https://doi.org/10.1002/acr.23337.; Fraenkel L., Bathon J.M., England B.R., et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021; 73 (7): 1108–23. https://doi.org/10.1002/art.41752.; Tarp S., Jorgensen T.S., Furst D.E., et al. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2019; 48 (6): 958–66. https://doi.org/10.1016/j.semarthrit.2018.10.002.; Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79 (6): 685–99. https://doi.org/10.1136/annrheumdis-2019-216655.; Gottlieb A., Merola J.F. Psoriatic arthritis for dermatologists. J Dermatolog Treat. 2020; 31 (7): 662–79. http://dx.doi.org/10.1080/09546634.2019.1605142.; Coates L.C., Kavanaugh A., Mease P.J., et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016; 68 (5): 1060–71. https://doi.org/10.1002/art.39573.; Montag K., Gingold M., Boers A., Littlejohn G. Disease-modifying antirheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. Intern Med J. 2011; 41 (6): 450–5. https://doi.org/10.1111/j.1445-5994.2010.02240.x.; Каратеев А.Е., Ермакова Ю.А., Березюк А.Н., Соловьева Е.С. Метотрексат и ингибиторы протонной помпы: имеется ли негативное фармакологическое взаимодействие? Научно-практическая ревматология. 2013; 51 (6): 662–5.; Iwaki M., Shimada H., Irino Y., et al. Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs. Biol Pharm Bull. 2017; 40 (6): 926–31. https://doi.org/10.1248/bpb.b16-00970.; Tracy T., Krohn K., Jones D., et al. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992; 42 (2): 121–5. https://doi.org/10.1007/bf00278469.; Bagatini F., Blatt C.R., Maliska G., et al. Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol. 2011; 51 (1): 29–39. https://doi.org/10.1590/S0482-50042011000100003.; Инструкция по медицинскому применению лекарственного препарата Метотрексат-РОНЦ®. Государственный реестр лекарственных средств. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0f1ca4f4-7407-4900-85de-e873e382f622 (дата обращения 16.07.2024).; https://www.pharmacoeconomics.ru/jour/article/view/1080

Διαθεσιμότητα: https://www.pharmacoeconomics.ru/jour/article/view/1080
https://doi.org/10.17749/2070-4909/farmakoekonomika.2024.273

Enhancing the Efficacy and Safety of Methotrexate Treatment: A Focus on Drug Interactions (Review) ; Повышение эффективности и безопасности использования метотрексата: фокус на лекарственные взаимодействия (обзор)

Συγγραφείς: S. A. Doktorova, Yu. Yu. Grabovetskaya, M. Stefanov, V. V. Rafalskiy, С. А. Докторова, Ю. Ю. Грабовецкая, М. Стефанов, В. В. Рафальский

Συνεισφορές: This research was supported by funds provided to the Immanuel Kant Baltic Federal University through the Russian Federal Academic Leadership Programme “Priority 2030” (project No. 123102600004-1)., Данная работа была поддержана из средств программы стратегического академического лидерства «Приоритет 2030» БФУ им. И. Канта, научный проект № 123102600004-1.

Πηγή: Safety and Risk of Pharmacotherapy; Том 12, № 3 (2024); 285-298 ; Безопасность и риск фармакотерапии; Том 12, № 3 (2024); 285-298 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2024-12-3

Θεματικοί όροι: нестероидные противовоспалительные препараты, drug interactions, adverse drug reactions, pharmacokinetics, pharmacodynamics, safety, rheumatoid arthritis, disease-modifying antirheumatic drugs, biologicals, proton pump inhibitors, non-steroidal anti-inflammatory drugs, лекарственные взаимодействия, нежелательные реакции, фармакокинетика, фармакодинамика, безопасность лекарственных средств, ревматоидный артрит, базисные противовоспалительные препараты, биологические препараты, ингибиторы протонной помпы

Περιγραφή αρχείου: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/416/1222; https://www.risksafety.ru/jour/article/view/416/1034; https://www.risksafety.ru/jour/article/view/416/1043; https://www.risksafety.ru/jour/article/view/416/1044; https://www.risksafety.ru/jour/article/view/416/1045; https://www.risksafety.ru/jour/article/view/416/1048; https://www.risksafety.ru/jour/article/view/416/1050; https://www.risksafety.ru/jour/article/view/416/1052; https://www.risksafety.ru/jour/article/view/416/1059; https://www.risksafety.ru/jour/article/view/416/1067; https://www.risksafety.ru/jour/article/view/416/1074; https://www.risksafety.ru/jour/article/view/416/1081; https://www.risksafety.ru/jour/article/downloadSuppFile/416/447; https://www.risksafety.ru/jour/article/downloadSuppFile/416/448; https://www.risksafety.ru/jour/article/downloadSuppFile/416/473; Weinblatt ME. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013;124:16–25. PMID: 23874006; Насонов ЕЛ, Каратеев ДЕ, Сатыбалдыев АМ, Лучихина ЕЛ, Лукина ГВ, Николенко МВ и др. Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I). Научно-практическая ревматология. 2016;54:50–62. https://doi.org/10.14412/1995-4484-2016-50-62; Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73–81. https://doi.org/10.1002/art.23144; Anghel L-A. Utilization patterns of disease-modifying antirheumatic drugs (DMARDs) in patients with autoimmune rheumatic diseases. Farmacia. 2019;67(1):184–92. https://doi.org/10.31925/farmacia.2019.1.25; Левитан АИ, Решетько ОВ. Реальная клиническая практика фармакотерапии ревматоидного артрита. Клиническая фармакология и терапия. 2019;28(1):44–9. https://doi.org/10.32756/0869-5490-2019-1-44-49; Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ, Лукина ГВ, Жиляев ЕВ, Амирджанова ВН и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» — 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477–94. https://doi.org/10.14412/1995-4484-2014-477-494; Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108–23. https://doi.org/10.1002/acr.24596; Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22(3):357–75. https://doi.org/10.1111/1756-185x.13513; Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. https://doi.org/10.1136/ard-2022-223356; Насонов ЕЛ, Амирджанова ВН, Олюнин ЮА, Муравьев ЮВ, Баранов АА, Зонова ЕВ и др. Применение метотрексата при ревматоидном артрите. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2023;61(4):435–49. https://doi.org/10.47360/1995-4484-2023-435-449; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2015;53(5s):32–50. https://doi.org/10.14412/1995-4484-2015-32-50; Tarp S, Jorgensen TS, Furst DE, Dossing A, Taylor PC, Choy EH, et al. Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum. 2019;48(6):958–66. https://doi.org/10.1016/j.semarthrit.2018.10.002; Silva MF, Ribeiro C, Goncalves VMF, Tiritan ME, Lima A. Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: a brief review. Biomed Chromatogr. 2018;32(5):e4159. https://doi.org/10.1002/bmc.4159; Bagatini F, Blatt CR, Maliska G, Trespash GV, Pereira IA, Zimmermann AF, et al. Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol. 2011;51(1):20–39. English, Portuguese. PMID: 21412604; Ma SN, Zaman Huri H, Yahya F. Drug-related problems in patients with rheumatoid arthritis. Ther Clin Risk Manag. 2019;15:505–24. https://doi.org/10.2147/TCRM.S194921; Jeong H, Baek SY, Kim SW, Eun YH, Kim IY, Kim H, et al. Comorbidities of rheumatoid arthritis: results from the Korean National Health and Nutrition Examination Survey. PLoS One. 2017;12(4):e0176260. https://doi.org/10.1371/journal.pone.0176260; Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, et al. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology. 2019;58(10):1767–76. https://doi.org/10.1093/rheumatology/kez037; Ye L, Yang-Huang J, Franse CB, Rukavina T, Vasiljev V, Mattace-Raso F, et al. Factors associated with polypharmacy and the high risk of medication-related problems among older community-dwelling adults in European countries: a longitudinal study. BMC Geriatr. 2022;22(1):841. https://doi.org/10.1186/s12877-022-03536-z; Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37(7):1416–21. https://doi.org/10.3899/jrheum.090153; Hall JJ, Bolina M, Chatterley T, Jamali F. Interaction between low-dose methotrexate and non-steroidal anti-inflammatory drugs, penicillins, and proton pump inhibitors. Ann Pharmacother. 2016;51(2):163–78. https://doi.org/10.1177/1060028016672035; Pflugbeil S, Böckl K, Pongratz R, Leitner M, Graninger W, Ortner A. Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatol Int. 2020;40(4):511–21. https://doi.org/10.1007/s00296-020-04526-3; Leveque D, Santucci R, Gourieux B, Herbrecht R. Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev Clin Pharmacol. 2011;4(6):743–50. https://doi.org/10.1586/ecp.11.57; Patane M, Ciriaco M, Chimirri S, Ursini F, Naty S, Grembiale RD, et al. Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis. Adv Pharmacol Sci. 2013;2013:313858. https://doi.org/10.1155/2013/313858; Desmoulin SK, Hou Z, Gangjee A, Matherly LH. The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol Ther. 2012;13(14):1355–73. https://doi.org/10.4161/cbt.22020; Bedoui Y, Guillot X, Selambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an old drug with new tricks. Int J Mol Sci. 2019;20(20).5023. https://doi.org/10.3390/ijms20205023; Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30(3):194–210. https://doi.org/10.2165/00003088-199630030-00002; Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645–8. PMID: 15088287; Bianchi G, Caporali R, Todoerti M, Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33(3):369–78. https://doi.org/10.1007/s12325-016-0295-8; Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, Cvejic J, Mooranian A, Al-Salami H, et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep. 2020;47(6):4699–708. https://doi.org/10.1007/s11033-020-05481-9; Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug–drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012;17(4):550–4. https://doi.org/10.1634/theoncologist.2011-0431; Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet. 2014;29(1):12–9. https://doi.org/10.2133/dmpk.dmpk-13-rv-119; Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1993;35(4):409–12. https://doi.org/10.1111/j.1365-2125.1993.tb04158.x; Lima A, Sousa H, Monteiro J, Azevedo R, Medeiros R, Seabra V. Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers. Pharmacogenomics. 2014;15(12):1611–35. https://doi.org/10.2217/pgs.14.116; Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics. 2011;21(10):679–86. https://doi.org/10.1097/FPC.0b013e328343dd93; Валиев ТТ, Семенова ВВ, Иконникова АЮ, Петрова АА, Белышева ТС, Наседкина ТВ. Роль фармакогенетических факторов в развитии побочных эффектов метотрексата при лечении злокачественных опухолей. Современная онкология. 2021;23(4):622–7. https://doi.org/10.26442/18151434.2021.4.201127; Murakami T, Mori N. Involvement of multiple transporters-mediated transports in mizoribine and methotrexate pharmacokinetics. Pharmaceuticals (Basel). 2012;5(8):802–36. https://doi.org/10.3390/ph5080802; Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76(3):907–12. https://doi.org/10.1172/JCI112088; Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem. 1999;32(7):519–36. https://doi.org/10.1016/s0009-9120(99)00052-1; Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet. 1986;1(8475):256–8. https://doi.org/10.1016/s0140-6736(86)90786-5; Ушкалова ЕА, Зырянов СК, Бутранова ОИ, Самсонова КИ. Метамизол натрия: регуляторный статус в разных странах мира, проблемы безопасности и ошибки применения. Безопасность и риск фармакотерапии. 2022;10(4):396–410. https://doi.org/10.30895/2312-7821-2022-10-4-396-410; Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, et al. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J Pharmacol Exp Ther. 2007;322(3):1162–70. https://doi.org/10.1124/jpet.107.121491; Glynn-Barnhart AM, Erzurum SC, Leff JA, Martin RJ, Cochran JE, Cott GR, Szefler SJ. Effect of low-dose methotrexate on the disposition of glucocorticoids and theophylline. J Allergy Clin Immunol. 1991;88(2):180–6. https://doi.org/10.1016/0091-6749(91)90326-j; Okada M, Fujii H, Suga Y, Morito S, Okada M, Nishigami J, et al. Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis. J Pharm Health Care Sci. 2017;3:7. https://doi.org/10.1186/s40780-017-0073-z; Ronchera CL, Hernández T, Peris JE, Torres F, Granero L, Jiménez NV, Plá JM. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit. 1993;15(5):375–9. https://doi.org/10.1097/00007691-199310000-00004; Al-Quteimat OM, Al-Badaineh MA. Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination. J Clin Pharm Ther. 2013;38(3):203–5. https://doi.org/10.1111/jcpt.12060; Hamid M, Lashari B, Ahsan I, Micaily I, Sarwar U, Crocetti J. A deadly prescription: combination of methotrexate and trimethoprim-sulfamethoxazole. J Community Hosp Intern Med Perspect. 2018;8(3):149–51. https://doi.org/10.1080/20009666.2018.1466598; Haider L, Sharif S, Hasan A, McFarlane IM. Low-dose methotrexate toxicity in the setting of vancomycin-induced acute kidney injury. Am J Med Case Rep. 2020;8(7):206–9. PMID: 32775622; Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol. 1993;33(1):82–4. https://doi.org/10.1007/BF00686028; Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP. Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ. 2002;324(7352):1497. https://doi.org/10.1136/bmj.324.7352.1497; Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs. 1994;47(1):25–50. https://doi.org/10.2165/00003495-199447010-00003; Miller DR, Letendre PW, DeJong DJ, Fiechtner JJ. Methotrexate in rheumatoid arthritis: an update. Pharmacotherapy. 1986;6(4):170–8. https://doi.org/10.1002/j.1875-9114.1986.tb03472.x; Kawase A, Yamamoto T, Egashira S, Iwaki M. Stereoselective inhibition of methotrexate excretion by glucuronides of nonsteroidal anti-inflammatory drugs via multidrug resistance proteins 2 and 4. J Pharmacol Exp Ther. 2016;356(2):366–74. https://doi.org/10.1124/jpet.115.229104; Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother. 1992;26(2):234–7. https://doi.org/10.1177/106002809202600219; van Roon EN, van de Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S27–32. PMID: 21044430; Grim J, Chládek J, Martínková J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet. 2003;42(2):139–51. https://doi.org/10.2165/00003088-200342020-00003; Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502–16. https://doi.org/10.1016/j.ejmech.2018.09.027; Gremese E, Alivernini S, Tolusso B, Zeidler MP, Ferraccioli G. JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. J Leukoc Biol. 2019;106(5):1063–8. https://doi.org/10.1002/JLB.5RU0519-145R; Hasko G, Cronstein B. Regulation of inflammation by adenosine. Front Immunol. 2013;4:85. https://doi.org/10.3389/fimmu.2013.00085; Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301–7. https://doi.org/10.1016/j.jbspin.2018.07.004; Thomas S, Fisher KH, Snowden JA, Danson SJ, Brown S, Zeidler MP. Methotrexate is a JAK/STAT pathway inhibitor. PLoS One. 2015;10(7):e0130078. https://doi.org/10.1371/journal.pone.0130078; Chinnaiya K, Lawson MA, Thomas S, Haider MT, Down J, Chantry AD, et al. Low-dose methotrexate in myeloproliferative neoplasm models. Haematologica. 2017;102(9):e336–e9. https://doi.org/10.3324/haematol.2017.165738; Solipuram V, Mohan A, Patel R, Ni R. Effect of Janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Auto Immun Highlights. 2021;12(1):8. https://doi.org/10.1186/s13317-021-00153-5; Panja S, Khatua DK, Halder M. Simultaneous binding of folic acid and methotrexate to human serum albumin: insights into the structural changes of protein and the location and competitive displacement of drugs. ACS Omega. 2018;3(1):246–53. https://doi.org/10.1021/acsomega.7b01437; Liu Y, Zhou S, Nissel J, Wu A, Lau H, Palmisano M. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis. Clin Pharmacol Drug Dev. 2014;3(6):456–65. https://doi.org/10.1002/cpdd.109; Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study I. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63(8):1150–8. https://doi.org/10.1002/acr.20494; Payne C, Zhang X, Shahri N, Williams W, Cannady E. AB0492 Evaluation of potential drug–drug interactions with baricitinib. Annals of the Rheumatic Diseases. 2015;74(Suppl 2):1063. https://doi.org/10.1136/annrheumdis-2015-eular.1627; Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev. 2016;2016(8):CD010227. https://doi.org/10.1002/14651858.CD010227.pub2; Xu Z, Davis HM, Zhou H. Clinical impact of concomitant immunomodulators on biologic therapy: pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharmacol. 2015;55 Suppl 3:S60–74. https://doi.org/10.1002/jcph.380; Schaeverbeke T, Truchetet ME, Kostine M, Barnetche T, Bannwarth B, Richez C. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford). 2016;55(2):210–20. https://doi.org/10.1093/rheumatology/kev277; Iwaki M, Shimada H, Irino Y, Take M, Egashira S. Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs. Biol Pharm Bull. 2017;40(6):926–31. https://doi.org/10.1248/bpb.b16-00970; Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992;42(2):121–5. https://doi.org/10.1007/BF00278469; Stewart CF, Fleming RA, Arkin CR, Evans WE. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther. 1990;47(4):540–6. https://doi.org/10.1038/clpt.1990.69; Skeith KJ, Russell AS, Jamali F, Coates J, Friedman H. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol. 1990;17(8):1008–10. PMID: 2213774; Combe B, Edno L, Lafforgue P, Bologna C, Bernard JC, Acquaviva P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol. 1995;34(5):421–8. https://doi.org/10.1093/rheumatology/34.5.421; Hubner G, Sander O, Degner FL, Turck D, Rau R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1997;24(5):845–51. PMID: 9150070; Iqbal MP, Baig JA, Ali AA, Niazi SK, Mehboobali N, Hussain MA. The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos. 1998;19(3):163–7. https://doi.org/10.1002/(sici)1099-081x(199804)19:33.0.co;2-l; Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokine tics in patients with rheumatoid arthritis. J Rheumatol. 1999;26(12):2539–43. PMID: 10606360; Hartmann SN, Rordorf CM, Milosavljev S, Branson JM, Chales GH, Juvin RR, et al. Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Ann Pharmacother. 2004;38(10):1582–7. https://doi.org/10.1345/aph.1E044; Schwartz JI, Agrawal NG, Wong PH, Miller J, Bachmann K, Marbury T, ey al. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol. 2009;49(10):1202–9. https://doi.org/10.1177/0091270009338939; Каратеев АЕ, Ермакова ЮА, Березюк АН, Соловьева ЕС. Метотрексат и ингибиторы протонной помпы — имеется ли негативное фармакологическое взаимодействие? Научно-практическая ревматология. 2013;51(6):662–5. https://doi.org/10.14412/1995-4484-2013-662-5; Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62(1):71–80. https://doi.org/10.1111/j.1365-2125.2005.02513.x; Vakily M, Amer F, Kukulka MJ, Andhivarothai N. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol. 2005;45(10):1179–86. https://doi.org/10.1177/0091270005280100; Shimada T, Nishimura Y, Funada Y, Takenaka K, Kobayashi K, Urata Y, et al. [A case of Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis and trimethoprim-sulphamethoxazole induced pancytopenia]. Arerugi. 2004;53(6):575–81. PMID: 15247519; Blum R, Seymour JF, Toner G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann Oncol. 2002;13(2):327–30. https://doi.org/10.1093/annonc/mdf021; Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26(4):578–81. https://doi.org/10.1007/s10067-005-0169-y; Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;72(12):1947–55. https://doi.org/10.1136/annrheumdis-2012-202220; Cohen S, Zwillich SH, Chow V, Labadie RR, Wilkinson B. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol. 2010;69(2):143–51. https://doi.org/10.1111/j.1365-2125.2009.03570.x; Zhu T, Moy S, Valluri U, Cao Y, Zhang W, Sawamoto T, et al. Investigation of potential drug–drug interactions between peficitinib (ASP015K) and methotrexate in patients with rheumatoid arthritis. Clin Drug Investig. 2020;40(9):827–38. https://doi.org/10.1007/s40261-020-00937-z; Gnjidic D, Le Couteur DG, Hilmer SN. Discontinuing drug treatments. BMJ. 2014;349:g7013. https://doi.org/10.1136/bmj.g7013; Akkara Veetil BM, Bongartz T. Perioperative care for patients with rheumatic diseases. Nat Rev Rheumatol. 2011;8(1):32–41. https://doi.org/10.1038/nrrheum.2011.171; Park JK, Kim MJ, Choi Y, Winthrop K, Song YW, Lee EB. Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials. Clin Rheumatol. 2020;39(2):375–9. https://doi.org/10.1007/s10067-019-04857-y; Lee J, Singh N, Gray SL, Makris UE. Optimizing medication use in older adults with rheumatic musculoskeletal diseases: deprescribing as an approach when less may be more. ACR Open Rheumatol. 2022;4(12):1031–41. https://doi.org/10.1002/acr2.11503; Сычев ДА, Остроумова ОД, Переверзев АП, Кочетков АИ, Остроумова ТМ, Клепикова МВ, Эбзеева ЕЮ. Пожилой и старческий возраст пациентов как фактор риска развития лекарственно-индуцированных заболеваний. Безопасность и риск фармакотерапии. 2021;9(1):15–24. https://doi.org/10.30895/2312-7821-2021-9-1-15-24; Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Inter Med. 2010;170(18): 1648–54. https://doi.org/10.1001/archinternmed.2010.355; Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1559–65. https://doi.org/10.1136/annrheumdis-2017-211128; Гриднева ГИ, Муравьев ЮВ, Лучихина ЕЛ, Демидова НВ, Каратеев ДЕ. Вопросы оптимизации терапии метотрексатом у больных ревматоидным артритом. Научно-практическая ревматология. 2017;55(1):41–7. https://doi.org/10.14412/1995-4484-2017-41-47; Hu Q, Wang H, Xu T. Predicting hepatotoxicity associated with low-dose methotrexate using machine learning. J Clin Med. 2023;12(4):1599. https://doi.org/10.3390/jcm12041599; Samal L, Khasnabish S, Foskett C, Zigmont K, Faxvaag A, Chang F, et al. Comparison of a voluntary safety reporting system to a global trigger tool for identifying adverse events in an oncology population. J Patient Saf. 2022;18(6):611–6. https://doi.org/10.1097/PTS.0000000000001050; https://www.risksafety.ru/jour/article/view/416

Διαθεσιμότητα: https://www.risksafety.ru/jour/article/view/416
https://doi.org/10.30895/2312-7821-2024-416

Rheumatoid arthritis and COVID-19: Three years later ; Ревматоидный артрит и COVID-19: три года спустя

Συγγραφείς: B. S. Belov, E. S. Aronova, G. I. Gridneva, E. I. Nasonov, Б. С. Белов, Е. С. Аронова, Г. И. Гриднева, Е. Л. Насонов

Συνεισφορές: Исследование выполнено в рамках темы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», № государственного задания 1021051503137-7

Πηγή: Rheumatology Science and Practice; Vol 61, No 4 (2023); 450-457 ; Научно-практическая ревматология; Vol 61, No 4 (2023); 450-457 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: базисные противовоспалительные препараты, infection, post-COVID syndrome, rheumatoid arthritis, immunoinflammatory rheumatic diseases, bDMARDs, DMARDs, инфекция, постковидный синдром, ревматоидный артрит, иммуновоспалительные ревматические заболевания, генно-инженерная биологическая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3399/2304; WHO coronavirus (COVID-19) dashboard. URL: https://covid19.who.int (Accessed: 31th May 2023).; Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-132. [Nasonov EL. Coronavirus disease 2019 (COVID-19): A rheumatologist’s thoughts. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(2):123-132 (In Russ.)]. doi:10.14412/1995-4484-2020-123-132; Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ, Лила АМ, Ананьева ЛП, Лисицина ТА, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-367. [Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: At the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(4):353-367 (In Russ.)]. doi:10.47360/1995-4484-2020-353-367; Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al.; NYU WARCOV Investigators. COVID-19 in patients with inflammatory arthritis: A prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol. 2020;72(12):1981-1989. doi:10.1002/art.41456; Conway R, Nikiphorou E, Demetriou CA, Low C, Leamy K, Ryan JG, et al.; COVID-19 Global Rheumatology Alliance. Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: Data from the COVID-19 global rheumatology alliance registry. Rheumatol Adv Pract. 2021;5(2):rkab031. doi:10.1093/rap/rkab031; D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi:10.1002/art.41619; Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi:10.1136/annrheumdis-2020-217871; Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi:10.1136/annrheumdis-2020-219498; Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137-1146. doi:10.1136/annrheumdis-2021-220418; England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. Risk of COVID-19 in rheumatoid arthritis: A national veterans affairs matched cohort study in at-risk individuals. Arthritis Rheumatol. 2021;73(12):2179-2188. doi:10.1002/art.41800; Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: First results of Reuma-CoV Brasil registry. RMD Open. 2021;7(1):e001461. doi:10.1136/rmdopen-2020-001461; Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark. Rheumatology (Oxford). 2021;60(SI):SI59-SI67. doi:10.1093/rheumatology/keaa897; FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE Consortium and Contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2021;80(4):527-538. doi:10.1136/annrheumdis-2020-218310; Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi:10.1136/rmdopen-2020-001464; Raiker R, DeYoung C, Pakhchanian H, Ahmed S, Kavadichanda C, Gupta L, et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum. 2021;51(5):1057-1066. doi:10.1016/j.semarthrit.2021.08.010; Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al.; ARTIS Study Group. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: A nationwide Swedish cohort study. Ann Rheum Dis. 2021;80(8):1086-1093. doi:10.1136/annrheumdis-2021-219845; Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Konstantonis G, et al. Different COVID-19 outcomes among systemic rheumatic diseases: A nation-wide cohort study. Rheumatology (Oxford). 2023;62(3):1047-1056. doi:10.1093/rheumatology/keac422; Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, et al.; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4(10):e2129639. doi:10.1001/jamanetworkopen.2021.29639; Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-García A, Tseng LY, et al.; COVID-19 Global Rheumatology Alliance. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766-775. doi:10.1002/art.42030; Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4; Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative. Ann Rheum Dis. 2016;75(6):965-973. doi:10.1136/annrheumdis-2016-209233; Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851-861. doi:10.1007/s00296-021-04803-9; Rutter M, Lanyon PC, Grainge MJ, Hubbard R, Peach E, Bythell M, et al. COVID-19 infection, admission and death among people with rare autoimmune rheumatic disease in England: Results from the RECORDER project. Rheumatology (Oxford). 2022;61(8):3161-3171. doi:10.1093/rheumatology/keab794; Patel NJ, D’Silva KM, Li MD, Hsu TYT, DiIorio M, Fu X, et al. Assessing the severity of COVID-19 lung injury in rheumatic diseases versus the general population using deep learning-derived chest radiograph scores. Arthritis Care Res (Hoboken). 2023;75(3):657-666. doi:10.1002/acr.24883; Hsu TY, D’Silva KM, Patel NJ, Wang J, Mueller AA, Fu X, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: A retrospective, comparative cohort study. Lancet Rheumatol. 2021;3(9):e638-e647. doi:10.1016/S2665-9913(21)00140-5; Fernandez-Gutierrez B, Leon L, Madrid A, Rodriguez-Rodriguez L, Freites D, Font J, et al. Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: Incidence and role of disease-modifying agents. Ther Adv Musculoskelet Dis. 2021;13:1759720X20962692. doi:10.1177/1759720X20962692; Насонов ЕЛ, Авдеева АС. Деплеция В-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (COVID-19). Научно-практическая ревматология. 2021;59(4):384-393. [Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus di sease 2019 (COVID-19). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):384-393 (In Russ.)]. doi:10.47360/1995-4484-2021-384-393; Regierer AC, Hasseli R, Schäfer M, Hoyer BF, Krause A, Lorenz HM, et al. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open. 2021;7(3):e001896. doi:10.1136/rmdopen-2021-001896; D’Silva KM, Wallace ZS. COVID-19 and rheumatoid arthritis. Curr Opin Rheumatol. 2021;33(3):255-261. doi:10.1097/BOR.0000000000000786; Li H, Wallace ZS, Sparks JA, Lu N, Wei J, Xie D, et al. Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: A general population study. Arthritis Care Res (Hoboken). 2023;75(5):956-966. doi:10.1002/acr.25028; Figueroa-Parra G, Gilbert EL, Valenzuela-Almada MO, Vallejo S, Neville MR, Patel NJ, et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: A retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 2022;4(11):e765-e774. doi:10.1016/S2665-9913(22)00227-2; Wang Y, D’Silva KM, Jorge AM, Li X, Lyv H, Wei J, et al. Increased risk of COVID-19 in patients with rheumatoid arthritis: A general population-based cohort study. Arthritis Care Res (Hoboken). 2022;74(5):741-747. doi:10.1002/acr.24831; Аронова ЕС, Белов БС, Гриднева ГИ. Постковидный синдром и ревматические заболевания: акцент на ревматоидный артрит (собственные данные). Медицинский совет. 2022;16(2):108-113. [Aronova ES, Belov BS, Gridneva GI. Post COVID syndrome and rheumatic diseases: Focus on rheumatoid arthritis (own data). Medical Council. 2022;16(2):108-113 (In Russ.)]. doi:10.21518/2079-701X-2022-16-2-108-113; Singh N, Madhira V, Hu C, Olex AL, Bergquist T, Fitzgerald KC, et al. Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C). Semin Arthritis Rheum. 2023;58:152149. doi:10.1016/j.semarthrit.2022.152149; Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28-33. doi:10.1038/s41591-020-01202-8; Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375(6585): 1122-1127. doi:10.1126/science.abm8108; Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. [Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(1):5-30 (In Russ.)]. doi:10.47360/1995-4484-2021-5-30; Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi:10.1038/s41584-019-0337-0; Raghav PK, Mann Z, Ahluwalia SK, Rajalingam R. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. J Pharmacol Sci. 2023;152(1):1-21. doi:10.1016/j.jphs.2023.02.004; Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci. 2022;92(4):398-403. doi:10.1134/S1019331622040062; Nasonov E, Samsonov M. The role of interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi:10.1016/j.biopha.2020.110698; WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for COVID-19 – Interim WHO Solidarity Trial results. N Engl J Med. 2021;384(6):497-511. doi:10.1056/NEJMoa2023184; Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19), версия 17 (09.12.2022). [Interim guidelines: Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19), version 17 (d.d. 12.09.2022) (In Russ.)]. URL: https://www.consultant.ru/document/cons_doc_LAW_347896/76f4d9e5aebc059b3c9a26fb6e57e2951afc8aca (Accessed: 27th May 2023).; van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi:10.1038/s41591-021-01643-9. Epub 2022 Jan 21. PMID: 35064248.; Schett G, Sticherling M, Neurath MF. COVID-19: Risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271-272. doi:10.1038/s41577-020-0312-7; Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9; Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194-202. doi:10.1038/s41590-021-01104-y; Di Iorio M, Cook CE, Vanni KMM, Patel NJ, D’Silva KM, Fu X, et al. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Semin Arthritis Rheum. 2022;55:152025. doi:10.1016/j.semarthrit.2022.152025; Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11(1):16144. doi:10.1038/s41598-021-95565-8; Calabrese LH. Long COVID in inflammatory rheumatic diseases – What’s in a name? Lancet Rheumatol. 2023;5(7):e364-e365. doi:10.1016/S2665-9913(23)00134-0; Zaccardelli A, Wallace ZS, Sparks JA. Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic. Curr Opin Rheumatol. 2023;35(3):175-184. doi:10.1097/BOR.0000000000000930; Насонов ЕЛ, Лила АМ, Белов БС, Аронова ЕС, Гриднева ГИ, Кудрявцева АВ, и др. Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы. Научно-практическая ревматология. 2021;59(6):666-675. [Nasonov EL, Belov BS, Lila AM, Aronova ES, Gridneva GI, Kudryavtseva AV, et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(6):666-675 (In Russ.)]. doi:10.47360/1995-4484-2021-666-675; Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y; Sen P, Naveen R, Nune A, Day J, Joshi M, Agarwal V, et al.; COVAD study group. Post-COVID-19 condition in patients with autoimmune rheumatic diseases: The COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Lancet Rheumatol. 2023;5(5):e247-e250. doi:10.1016/S2665-9913(23)00066-8; Widdifield J, Kwong JC, Chen S, Eder L, Benchimol EI, Kaplan GG, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: A population-based analysis. Lancet Rheumatol. 2022;4(6):e430-e440. doi:10.1016/S2665-9913(22)00096-0; Белов БС, Муравьева НВ, Куликов АН. Иммуногенность вакцин против SARS-CoV-2 у пациентов с ревматическими заболеваниями. Антибиотики и химиотерапия. 2022;67(5-6):70-80. [Belov BS, Muravyeva NV, Kulikov AN. Immunogenicity of vaccines against SARS-CoV-2 in patients with rheumatic diseases. Antibiotics and Chemotherapy. 2022;67(5-6):70-80 (In Russ.)]. doi:10.37489/0235-2990-2022-67-5-6-70-80; Skapenko A, Schulze-Koops H. COVID-19 vaccination in individuals with inflammatory rheumatic diseases. Nat Rev Rheumatol. 2023;19(2):76-77. doi:10.1038/s41584-022-00892-3; Vanni KM, Patel NJ, DiIorio M, Kowalski E, Qian G, Cook CE, et al. Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: Two cases in patients on TNF inhibitor monotherapy. RMD Open. 2022;8(1):e002082. doi:10.1136/rmdopen-2021-002082; Patel NJ, Wang X, Fu X, Kawano Y, Cook C, Vanni KMM, et al. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. Semin Arthritis Rheum. 2023;58:152108. doi:10.1016/j.semarthrit.2022.152108; Cordtz R, Kristensen S, Westermann R, Duch K, Pearce F, Lindhardsen J, et al. COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis. Rheumatology (Oxford). 2022;62(1):77-88. doi:10.1093/rheumatology/keac241; Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: A prospective, cohort study. Lancet Rheumatol. 2022;4(3):e177-e187. doi:10.1016/S2665-9913(21)00394-5; Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386-401. doi:10.1111/imm.13443; Watanabe T, Minaga K, Hara A, Yoshikawa T, Kamata K, Kudo M. Case report: New-onset rheumatoid arthritis following COVID-19 vaccination. Front Immunol. 2022;13:859926. doi:10.3389/fimmu.2022.859926; Safary A, Esalatmanesh K, Eftekharsadat AT, Jafari Nakjavani MR, Khabbazi A. Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination. Int Immunopharmacol. 2022;110:109061. doi:10.1016/j.intimp.2022.109061; Белов БС, Лила АМ, Насонов ЕЛ. Вакцинация против SARS-CoV-2 при ревматических заболеваниях: вопросы безопасности. Научно-практическая ревматология. 2022;60(1):21-31. [Belov BS, Lila AM, Nasonov EL. Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(1):21-31 (In Russ.)]. doi:10.47360/1995-4484-2022-21-31; Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 5. Arthritis Rheumatol. 2023;75(1):E1-E16. doi:10.1002/art.42372; Tavares ACFMG, de Melo AKG, Cruz VA, de Souza VA, de Carvalho JS, Machado KLLL, et al. Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: A Brazilian Society of Rheumatology task force. Adv Rheumatol. 2022;62(1):3. doi:10.1186/s42358-022-00234-7; Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. [Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):239-254 (In Russ.)]. doi:10.47360/1995-4484-2021-239-254

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3399
https://doi.org/10.47360/1995-4484-2023-450-457

Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022 ; Обновленные рекомендации Американской коллегии ревматологов/Американской ассоциации хирургов тазобедренного и коленного суставов по периоперационному назначению противоревматических препаратов пациентам с ревматическими заболеваниями, которым выполняется тотальное эндопротезирование тазобедренного или коленного сустава 2022

Συγγραφείς: V. N. Amirjanova, M. A. Makarov, A. E. Karateev, A. E. Khramov, S. V. Maglevaniy, A. V. Rozov, V. A. Nesterenko, E. L. Nasonov, В. Н. Амирджанова, М. А. Макаров, А. Е. Каратеев, А. Э. Храмов, С. В. Маглеваный, А. В. Розов, В. А. Нестеренко, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 61, No 3 (2023); 260-267 ; Научно-практическая ревматология; Vol 61, No 3 (2023); 260-267 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: глюкокортикоиды, joint replacement, rheumatic diseases, basic anti-inflammatory drugs, genetically engineered biological drugs, janus kinases, glucocorticoids, эндопротезирование суставов, ревматические заболевания, базисные противовоспалительные препараты, генно-инженерные биологические препараты, янус-киназы

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3353/2281; Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, van Voorhees AS, Armstrong AW, et al. From the medical board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2016;75:798-805.e7. doi:10.1016/j.jaad.2016.06.014; Лила АМ, Насонов ЕЛ, Коротаева ТВ. Псориатический артрит: патогенетические особенности и инновационные методы терапии. Научно-практическая ревматология. 2018;56(6):685-691. doi:10.14412/1995-4484-2018-685-691; Tung K, Lee Y, Lin C, Lee C, Lin M, Wei JC. Opposing trends in total knee and hip arthroplasties for patients with rheumatoid arthritis vs. the general population: A 14-year retrospective study in Taiwan. Front Med. 2021;8:502. doi:10.3389/fmed.2021.640275; Mertelsmann-Voss C, Lyman S, Pan TJ, Goodman S, Figgie MP, Mandl LA. Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991–2005. J Rheumatol. 2014;41:867-874. doi:10.3899/jrheum.130617; Nikiphorou E, Carpenter L, Morris S, Macgregor AJ, Dixey J, Kiely P, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: Results from two UK inception cohorts. Arthritis Rheumatol. 2014;66:1081-1089. doi:10.1002/art.38344; Richter MD, Crowson CS, Matteson EL, Makol A. Orthopedic surgery among patients with rheumatoid arthritis: A population-based study to identify risk factors, sex differences, and time trends. Arthritis Care Res (Hoboken). 2018;70(10):546-1550. doi:10.1002/acr.23499; Ward MM. Risk of total knee arthroplasty in young and middleaged adults with ankylosing spondylitis. Clin Rheumatol. 2018;37: 3431-3433. doi:10.1007/s10067-018-4246-4; Ravi B, Croxford R, Hollands S, Paterson JM, Bogoch E, Kreder H, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(2):254-263. doi:10.1002/art.38231; Richardson SS, Kahlenberg CA, Goodman SM, Russell LA, Sculco TP, Sculco PK, et al. Inflammatory arthritis is a risk factor for multiple complications after total hip arthroplasty: A population-based comparative study of 68,348 patients. J Arthroplasty. 2019;34:1150-1154.e2. doi:10.1016/j.arth.2019.02.018; Goodman SM, Miller AS, Turgunbaev M, Guyatt G, Yates A, Springer B, et al. Clinical practice guidelines: incorporating input from a patient panel. Arthritis Care Res (Hoboken). 2017;69:1125-1130. doi:10.1002/acr.23275; Goodman SM, Bykerk VP, DiCarlo E, Cummings RW, Donlin LT, Orange DE, et al. Flares in patients with rheumatoid arthritis after total hip and total knee arthroplasty: Rates, characteristics, and risk factors. J Rheumatol. 2018;45:604-611. doi:10.3899/jrheum.170366; Goodman SM, Mirza SZ, DiCarlo EF, Pearce-Fisher D, Zhang M, Mehta B, et al. Rheumatoid arthritis flares after total hip and total knee arthroplasty: Outcomes at one year. Arthritis Care Res (Hoboken). 2020;72:925-932. doi:10.1002/acr.24091; Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785-791. doi:10.1136/ard.2010.128637; Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-2300. doi:10.1002/art.10529; Cordtz RL, Zobbe K, Højgaard P, Kristensen LE, Overgaard S, Odgaard A, et al. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: A nationwide cohort study using Danish healthcare registers. Ann Rheum Dis. 2018;77:281. doi:10.1136/annrheumdis-2017-212339; Goodman SM, Springer BD, Chen AF, Davis M, Fernandez DR, Figgie M, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheum. 2022;74(9):1464-1473. doi:10.1002/art.42140; Михельс Х, Никишина ИП, Федоров ЕС, Салугина СО. Генноинженерная биологическая терапия ювенильного артрита. Научно-практическая ревматология. 2011;49(1):78-93. doi:10.14412/1995-4484-2011-873; Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. 2017;69:1538-1551. doi:10.1002/art.40149; Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):746-747. doi:10.2106/JBJS.9408.ebo746; Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl 2):e278S-e325S. doi:10.1378/chest.11-2404; Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleisch mann KE, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009;120(21):e169-e276. doi:10.1161/CIRCULATIONAHA.109.192690; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2009;54(22):e13-e118. doi:10.1016/j.jacc.2009.07.010; Логинова ЕЮ, Корсакова ЮЛ, Колтакова АД, Губарь ЕЕ, Карпова ПЛ, Глухова СИ, и др. Эффективность и безопас ность апремиласта у больных псориатическим артритом в сочетании с коморбидной патологией в клинической прак тике. Научнопрактическая ревматология. 2019;57(3):299-306. doi:10.14412/1995-4484-2019-299-306; Hernigou P, Dubory A, Potage D, Roubineau F, Flouzat-Lachaniette CH. Outcome of knee revisions for osteoarthritis and inflammatory arthritis with postero-stabilized arthroplasties: A mean ten-year follow-up with 9 0 knee revisions. Int Orthop. 2017;41(4):757-763. doi:10.1007/s00264-016-3319-8; Ren Y, Yang Q, Luo T, Lin J, Jin J, Qian W, et al. Better clinical outcome of total knee arthroplasty for rheumatoid arthritis with perioperative glucocorticoids and disease-modifying antirheumatic drugs after an average of 11.4-year follow-up. J Orthop Surg Res. 2021;16(1):84. doi:10.1186/s13018-021-02232-9; Borgas Y, Gülfe A, Kindt M, Stefansdottir A. Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties. BMC Musculoskelet Disord. 2020;21(1):410. doi:10.1186/s12891-020-03459-z; George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, et al. Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty. Arthritis Care Res (Hoboken). 2017;69(12):1845-1854. doi:10.1002/acr.23209; George MD, Baker JF, Winthrop K, Alemao E, Chen L, Connolly S, et al. Timing of abatacept before elective arthroplasty and risk of postoperative outcomes. Arthritis Care Res (Hoboken). 2019;71(9):1224-1233. doi:10.1002/acr.23843; Насонов ЕЛ. Перспективы анти-В-клеточной терапии в ревматологии. Научно-практическая ревматология. 2018;56(5): 539-548. doi:10.14412/1995-4484-2018-539-548; Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62-79. doi:10.14412/1995-4484-2020-62-79; Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть II). Научно-практическая ревматология. 2020;58(2):214-224. doi:10.14412/1995-4484-2020-214-224; Авдеева АС, Мисиюк АС, Сатыбалдыев АМ, Лукина ГВ, Сороцкая ВН, Жиляев ЕВ, и др. Анализ результатов терапии тофацитинибом в реальной клинической практике (по данным Общероссийского регистра больных артритом ОРЕЛ). Научно-практическая ревматология. 2020;58(3):262-267. doi:10.14412/1995-4484-2020-262-267; Kaine J, Tesser J, Takiya L, DeMasi R, Wang L, Snyder M, et al. Reestablishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis. Clin Rheumatol. 2020;39(7):2127-2137. doi:10.1007/s10067-020-04956-1; Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi:10.14412/1995-4484-2019-8-16; Насонов ЕЛ, Денисов ЛН, Станислав МИ. Новые аспекты фармакотерапии ревматоидного артрита: ингибиторы малых молекул. Научно-практическая ревматология. 2012;50(2):66-75. doi:10.14412/1995-4484-2012-1276; Насонов ЕЛ, Коротаева ТВ. Ингибиторы Янус-киназ при иммуновоспалительных заболеваниях: 10 лет клинической практики в ревматологии. Научно-практическая ревматология. 2022;60(2): 131-148. doi:10.47360/1995-4484-2022-131-148; Муханов ВВ, Рыбников АВ, Попкова ТВ, Макаров МА. Эндопротезирование тазобедренных суставов у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2020;58(2):191-197. doi:10.14412/1995-4484-2020-191-197; Насонов ЕЛ, Авдеева АС, Попкова ТВ. Новые возможности фармакотерапии системной красной волчанки: перспективы применения анифролумаба (моноклональные антитела к рецепторам интерферона типа I). Научно-практическая ревматология. 2021;59(5):537-546. doi:10.47360/1995-4484-2021-537-546; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi:10.47360/1995-4484-2021-367-383; Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731. doi:10.1016/S0140-6736(10)61354-2; Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668. doi:10.1002/14651858.CD010668.pub2; Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. doi:10.1136/annrheumdis-2019-215089; Fein AW, Figgie CA, Dodds TR, Wright-Chisem J, Parks ML, Mandl LA, et al. Systemic lupus erythematosus does not increase risk of adverse events in the first 6 months after total knee arthroplasty. J Clin Rheumatol. 2016;22(7):355-359. doi:10.1097/RHU.0000000000000435; Merayo-Chalico J, Gónzalez-Contreras M, Ortíz-Hernández R, Alcocer-Varela J, Marcial D, Gómez-Martín D. Total hip arthroplasty outcomes: An 18-year experience in a single center: Is systemic lupus erythematosus a potential risk factor for adverse outcomes? J Arthroplasty. 2017;32(11):3462-3467. doi:10.1016/j.arth.2017.06.021; Li Z, Du Y, Xiang S, Feng B, Bian Y, Qian W, et al. Risk factors of perioperative complications and transfusion following total hip arthroplasty in systemic lupus erythematosus patients. Lupus. 2019;28(9):1134-1140. doi:10.1177/0961203319862609; Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169. doi:10.1001/jamanetworkopen.2018.4169; Chukir T, Goodman SM, Tornberg H, Do H, Thomas C, Sigmund A, et al. Perioperative glucocorticoids in patients with rheumatoid arthritis having total joint replacements: Help or harm? ACR Open Rheumatol. 2021;3(9):654-659. doi:10.1002/acr2.11306; Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316. doi:10.14412/1995-4484-2020-304-316; Насонов ЕЛ, Лила АМ. Перспективы применения упадацитиниба при ревматоидном артрите и других иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2020;58(5):532-543. doi:10.47360/1995-4484-2020-532-543; Насонов ЕЛ, Коротаева ТВ, Дубинина ТВ, Лила АМ. Ингибиторы ИЛ23/ИЛ17 при иммуновоспалительных ревматических заболеваниях: новые горизонты. Научно-практическая ревматология. 2019;57(4):400-406. doi:10.14412/1995-4484-2019-400-406; Lopez-Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez-Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356. doi:10.1002/14651858.CD007356.pub2; Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview. CMAJ. 2009;181(11):787-796. doi:10.1503/cmaj.091391; Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;2009(4):CD007277. doi:10.1002/14651858.CD007277.pub2; Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al.; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-920. doi:10.1136/ard.2010.144998; Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al.; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625-2632. doi:10.1002/art.27555

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3353
https://doi.org/10.47360/1995-4484-2023-260-267

COVID-19 and post-covid syndrome in patients with rheumatoid arthritis ; COVID-19 и постковидный синдром у больных ревматоидным артритом

Συγγραφείς: E. S. Aronova, B. S. Belov, G. I. Gridneva, Е. С. Аронова, Б. С. Белов, Г. И. Гриднева

Συνεισφορές: The investigation has been conducted within scientific topic № 1021051503137-7 as a part of government task., Статья подготовлена в рамках научно-исследовательской работы, № государственного задания 1021051503137-7.

Πηγή: Modern Rheumatology Journal; Том 17, № 4 (2023); 71-74 ; Современная ревматология; Том 17, № 4 (2023); 71-74 ; 2310-158X ; 1996-7012

Θεματικοί όροι: базисные противовоспалительные препараты, infection, post-covid syndrome, rheumatoid arthritis, immunoinflammatory rheumatic diseases, biological disease modifying antirheumatic drugs, disease modifying antirheumatic drugs, инфекция, постковидный синдром, ревматоидный артрит, иммуновоспалительные ревматические заболевания, генно-инженерные биологические препараты

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1462/1387; Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019 Jan 1;170(1):ITC1-ITC16. doi:10.7326/AITC201901010.; Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019 Nov;78(11):1463-1471. doi:10.1136/annrheumdis-2019-215920. Epub 2019 Sep 11.; Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022 Apr;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9. Epub 2021 Dec 21.; Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-866. doi:10.1136/annrheumdis-2020-217871. Epub 2020 May 29.; Izadi Z, Gianfrancesco MA, Aguirre A, et al. Development of a prediction model for COVID-19 acute respiratory distress syndrome in patients with rheumatic diseases: results from the Global Rheumatology Alliance registry. ACR Open Rheumatol. 2022 Oct;4(10):872-882. doi:10.1002/acr2.11481. Epub 2022 Jul 22.; Strangfeld A, Schafer M, Gianfrancesco MA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 Jul; 80(7):930-942. doi:10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.; Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639. doi:10.1001/jamanetworkopen.2021.29639.; Gianfrancesco MA, Leykina LA, Izadi Z, et al. Association of race and ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 Global Rheumatology Alliance Physician registry. Arthritis Rheumatol. 2021 Mar;73(3):374-380. doi:10.1002/art.41567. Epub 2021 Feb 2.; Izadi Z, Gianfrancesco MA, Schmajuk G, et al. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study. Lancet Rheumatol. 2022 Sep;4(9):e603-e613. doi:10.1016/S2665-9913(22)00192-8. Epub 2022 Jul 25.; Conway R, Grimshaw AA, Konig MF, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022 May;74(5):766-775. doi:10.1002/art.42030. Epub 2022 Mar 28.; Paik JJ, Sparks JA, Kim AHJ. Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. Curr Opin Pharmacol. 2022 Aug;65:102243. doi:10.1016/j.coph.2022.102243. Epub 2022 May 2.; D'Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot'. Ann Rheum Dis. 2020 Sep;79(9):1156-1162. doi:10.1136/annrheumdis-2020-217888. Epub 2020 May 26.; Hsu TY, D'Silva KM, Patel NJ, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. Lancet Rheumatol. 2021 Sep;3(9): e638-e647. doi:10.1016/S2665-9913(21)00140-5. Epub 2021 May 28.; Patel NJ, D'Silva KM, Li MD, et al. Assessing the Severity of COVID-19 Lung Injury in Rheumatic Diseases Versus the General Population Using Deep Learning-Derived Chest Radiograph Scores. Arthritis Care Res (Hoboken). 2023 Mar;75(3):657-666. doi:10.1002/acr.24883.; D'Silva KM, Serling-Boyd N, Hsu TY, et al. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. Ann Rheum Dis. 2021 Jun;80(6):817-819. doi:10.1136/annrheumdis-2020-219808. Epub 2021 Jan 12.; England BR, Roul P, Yang Y, et al. Risk of COVID-19 in rheumatoid arthritis: a national veterans affairs matched cohort study in atrisk individuals. Arthritis Rheumatol. 2021 Dec;73(12):2179-2188. doi:10.1002/art.41800. Epub 2021 Oct 19.; Wang Y, D'Silva KM, Jorge AM, et al. Increased risk of COVID-19 in patients with rheumatoid arthritis: a general population-based cohort study. Arthritis Care Res (Hoboken). 2022 May;74(5):741-747. doi:10.1002/acr.24831. Epub 2022 Mar 8.; Vergnes JN. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2021 Apr 22;384(16):1577. doi:10.1056/NEJMc2036242. Epub 2021 Feb 17.; Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi:10.1056/NEJMoa2035389. Epub 2020 Dec 30.; Widdifield J, Kwong JC, Chen S, et al. Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021 in Ontario, Canada: a population-based analysis. Lancet Rheumatol. 2022 Jun;4(6): e430-e440. doi:10.1016/S2665-9913(22)00096-0. Epub 2022 Apr 14.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1462
https://doi.org/10.14412/1996-7012-2023-4-71-74

RA-associated atherosclerosis: mechanisms of development and therapeutic perspectives ; Иммуновоспалительные механизмы развития РА-ассо- циированного атеросклероза: перспективные направления оптимизации терапевтической стратегии

Συγγραφείς: V. I. Ponkratov, N. S. Mescherina, В. И. Понкратов, Н. С. Мещерина

Πηγή: Complex Issues of Cardiovascular Diseases; Том 11, № 4 (2022); 105-117 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 11, № 4 (2022); 105-117 ; 2587-9537 ; 2306-1278

Θεματικοί όροι: Генно-инженерные биологические препараты, Cardiovascular risk, Cardiovascular diseases, Atherosclerosis, Disease-modifying antirheumatic drugs, Biological drugs, Сердечно-сосудистый риск, Сердечно-сосудистые заболевания, Атеросклероз, Базисные противовоспалительные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://www.nii-kpssz.com/jour/article/view/1245/719; van den Hoek J., Boshuizen H.C., Roorda L.D., Tijhuis G.J., Nurmohamed M.T., van den Bos G.A., Dekker J. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017;37(4):487-493. doi:10.1007/s00296-016-3638-5.; Liao K.P., Huang J., He Z., Cremone G., Lam E., Hainer J.M., Morgan V., Bibbo C., Di Carli M. Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus and Association With All-Cause Mortality. Arthritis Care Res (Hoboken). 2021; 73(2):159-165. doi:10.1002/acr.24108.; Agca R., Heslinga S.C., Rollefstad S., Heslinga M., McInnes I.B., Peters M.J., Kvien T.K., Dougados M., Radner H., Atzeni F., Primdahl J., Södergren A., Wallberg Jonsson S., van Rompay J., Zabalan C., Pedersen T.R., Jacobsson L., de Vlam K., Gonzalez-Gay M.A., Semb A.G., Kitas G.D., Smulders Y.M., Szekanecz Z., Sattar N., Symmons D.P., Nurmohamed M.T. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017; 76(1):17-28. doi:10.1136/annrheumdis-2016-209775.; Лунева Ю.В., Поветкин С.В., Сараев И.А., Артюшкова Е.Б. Возможности современной комбинированной фармакотерапии у больных с сочетанной сердечно-сосудистой патологией в условиях амбулаторной практики. Курский научно-практический вестник «Человек и его здоровье». 2019;(4):21-30. doi:10.21626/vestnik/2019-4/03; Ghosh-Swaby O.R., Kuriya B. Awareness and perceived risk of cardiovascular disease among individuals living with rheumatoid arthritis is low: results of a systematic literature review. Arthritis Res Ther. 2019; 21(1):33. doi:10.1186/s13075-019-1817-y.; DeMizio D.J., Geraldino-Pardilla L.B. Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis. Rheumatol Ther. 2020; 7(1):19-33. doi:10.1007/s40744-019-00189-0.; Karpouzas G.A., Malpeso J., Choi T.Y., Li D., Munoz S., Budoff M.J. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann Rheum Dis. 2014; 73(10):1797-804. doi:10.1136/annrheumdis-2013-203617.; Løgstrup B.B., Olesen K.K.W., Masic D., Gyldenkerne C., Thrane P.G., Ellingsen T., Bøtker H.E., Maeng M. Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease. Ann Rheum Dis. 2020; 79(9):1182-1188. doi:10.1136/annrheumdis-2020-217154.; Arts E.E., Popa C.D., Den Broeder A.A., Donders R., Sandoo A., Toms T., Rollefstad S., Ikdahl E., Semb A.G., Kitas G.D., Van Riel P.L., Fransen J. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis. 2016; 75(4):674-80. doi:10.1136/annrheumdis-2014-206879.; Маркин А.М., Маркина Ю.В., Толстик Т.В., Богатырева А.И., Собенин И.А., Орехов А.Н. Влияние воспаления и мутаций митохондриального генома на клеточные механизмы атерогенеза. Комплексные проблемы сердечно-сосудистых заболеваний. 2020;9(4): 80-87. doi:10.17802/2306-1278-2020-9-4-80-87.; Winchester R., Giles J.T., Nativ S., Downer K., Zhang H.Z., Bag-Ozbek A., Zartoshti A., Bokhari S., Bathon J.M. Association of Elevations of Specific T Cell and Monocyte Subpopulations in Rheumatoid Arthritis With Subclinical Coronary Artery Atherosclerosis. Arthritis Rheumatol. 2016; 68(1):92-102. doi:10.1002/art.39419.; Crowson C.S., Rollefstad S., Ikdahl E., Kitas G.D., van Riel P.L.C.M., Gabriel S.E., Matteson E.L., Kvien T.K., Douglas K., Sandoo A., Arts E., Wållberg-Jonsson S., Innala L., Karpouzas G., Dessein P.H., Tsang L., El-Gabalawy H., Hitchon C., Ramos V.P., Yáñez I.C., Sfikakis P.P., Zampeli E., Gonzalez-Gay M.A., Corrales A., Laar M.V., Vonkeman H.E., Meek I., Semb A.G.; A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA). Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018; 77(1):48-54. doi:10.1136/annrheumdis-2017-211735.; Di Minno M.N., Ambrosino P., Lupoli R., Di Minno A., Tasso M., Peluso R., Tremoli E. Clinical assessment of endothelial function in patients with rheumatoid arthritis: A meta-analysis of literature studies. Eur J Intern Med. 2015; 26(10):835-42. doi:10.1016/j.ejim.2015.10.016.; Ikdahl E., Hisdal J., Rollefstad S., Olsen I.C., Kvien T.K., Pedersen T.R., Semb A.G. Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. Arthritis Res Ther. 2015; 17:279. doi:10.1186/s13075-015-0795-y.; Михин В.П., Воротынцева В.В., Громнацкий Н.И., Аникин В.В. Изменения эластичности сосудистой стенки артерий и маркеров ангиопатии на фоне длительной терапии статинами больных артериальной гипертонией с высоким сердечно-сосудистым риском. Курский научно-практический вестник «Человек и его здоровье». 2020;(4):37-45. doi:10.21626/vestnik/2020-4/05; Hashizume M., Mihara M. Atherogenic effects of TNF-alpha and IL-6 via up-regulation of scavenger receptors. Cytokine 2012; 58:424–430. doi:10.1016/j.cyto.2012.02.010.; Bacchiega B.C., Bacchiega A.B., Usnayo M.J., Bedirian R., Singh G., Pinheiro G.D. Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J Am Heart Assoc. 2017; 6(3):e005038. doi:10.1161/JAHA.116.005038.; Sokolove J., Bromberg R., Deane K.D., Lahey L.J., Derber L.A., Chandra P.E., Edison J.D., Gilliland W.R., Tibshirani R.J., Norris J.M., Holers V.M., Robinson W.H. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012; 7(5):e35296. doi:10.1371/journal.pone.0035296.; Sokolove J., Brennan M.J., Sharpe O., Lahey L.J., Kao A.H., Krishnan E., Edmundowicz D., Lepus C.M., Wasko M.C., Robinson W.H. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum. 2013; 65(7):1719-24. doi:10.1002/art.37961.; Giles J.T., Fert-Bober J., Park J.K., Bingham C.O. 3rd, Andrade F., Fox-Talbot K., Pappas D., Rosen A., van Eyk J., Bathon J.M., Halushka M.K. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther. 2012; 14(1):R39. doi:10.1186/ar3752.; Geraldino-Pardilla L., Russo C., Sokolove J., Robinson W.H., Zartoshti A., Van Eyk J., Fert-Bober J., Lima J., Giles J.T., Bathon J.M. Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis. Rheumatology (Oxford). 2017; 56(4):534-540. doi:10.1093/rheumatology/kew436.; Klingenberg R., Luscher T.F. Rheumatoid arthritis and coronary atherosclerosis: two cousins engaging in a dangerous liaison. Eur Heart J 2015; 36:3423–3425. doi:10.1093/eurheartj/ehv489.; Zeisbrich M., Yanes R.E., Zhang H., Watanabe R., Li Y., Brosig L., Hong J., Wallis B.B., Giacomini J.C., Assimes T.L., Goronzy J.J., Weyand C.M. Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation. Ann Rheum Dis. 2018; 77(7):1053-1062. doi:10.1136/annrheumdis-2017-212647.; Moreno-Navarrete J.M., Fernandez-Real J.M. The complement system is dysfunctional in metabolic disease: evidences in plasma and adipose tissue from obese and insulin resistant subjects. Semin Cell Dev Biol 2019; 85:164–172. doi:10.1016/j.semcdb.2017.10.025.; Shields K.J., Mollnes T.E., Eidet J.R., Mikkelsen K., Almdahl S.M., Bottazzi B., Lyberg T., Manzi S., Ahearn J.M., Hollan I. Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases. PLoS One. 2017; 12(3):e0174577. doi:10.1371/journal.pone.0174577.; England B.R., Thiele G.M., Anderson D.R., Mikuls T.R. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018; 361:k1036. doi:10.1136/bmj.k1036.; Singh S., Fumery M., Singh A.G., Singh N., Prokop L.J., Dulai P.S., Sandborn W.J., Curtis J.R. Comparative Risk of Cardiovascular Events With Biologic and Synthetic DiseaseModifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020; 72(4):561-576. doi:10.1002/acr.23875.; del Rincón I., Battafarano D.F., Restrepo J.F., Erikson J.M., Escalante A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 2014 Feb;66(2):264-72. doi:10.1002/art.38210.; Roubille C., Richer V., Starnino T., McCourt C., McFarlane A., Fleming P., Siu S., Kraft J., Lynde C., Pope J., Gulliver W., Keeling S., Dutz J., Bessette L., Bissonnette R., Haraoui B. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and metaanalysis. Ann Rheum Dis. 2015; 74(3):480-9. doi:10.1136/annrheumdis-2014-206624.; Widdifield J., Abrahamowicz M., Paterson J.M., Huang A., Thorne J.C., Pope J.E., Kuriya B., Beauchamp M.E., Bernatsky S. Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis. J Rheumatol. 2019; 46(5):467-474. doi:10.3899/jrheum.180427.; Charles-Schoeman C., Wang X., Lee Y.Y., Shahbazian A., Navarro-Millán I., Yang S., Chen L., Cofield S.S., Moreland L.W., O'Dell J., Bathon J.M., Paulus H., Bridges S.L.Jr., Curtis J.R. Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheumatol. 2016; 68(3):577-86. doi:10.1002/art.39502.; Johnson T.M., Sayles H.R., Baker J.F., George M.D., Roul P., Zheng C., Sauer B., Liao K.P., Anderson D.R., Mikuls T.R., England B.R. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. Ann Rheum Dis. 2021;80(11):1385- 1392. doi:10.1136/annrheumdis-2021-220125.; Князева Л.А., Князева Л.И., Мещерина Н.С., Горяйнов И.И., Понкратов В.И. Изменение показателей эндотелиальной функции и жесткости артериального русла у больных ревматоидным артритом на фоне терапии лефлуномидом. Курский научно-практический вестник «Человек и его здоровье». 2016;(2):20-28. doi:10.21626/vestnik/2016-2/04.; Barnabe C., Martin B.J., Ghali W.A. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011; 63(4):522-9. doi:10.1002/acr.20371.; Ljung L., Rantapää-Dahlqvist S., Jacobsson L.T., Askling J. Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Ann Rheum Dis. 2016; 75(12):2087-2094. doi:10.1136/annrheumdis-2015-208995.; Jin Y., Kang E.H., Brill G., Desai R.J., Kim S.C. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J Rheumatol. 2018; 45(9):1240-1248. doi:10.3899/jrheum.170926.; McInnes I.B., Thompson L., Giles J.T., Bathon J.M., Salmon J.E., Beaulieu A.D., Codding C.E., Carlson T.H., Delles C., Lee J.S., Sattar N. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015; 74(4):694-702. doi:10.1136/annrheumdis-2013-204345.; Kleveland O., Ueland T., Kunszt G., Bratlie M., Yndestad A., Broch K., Holte E., Ryan L., Amundsen B.H., Bendz B., Aakhus S., Espevik T., Halvorsen B., Mollnes T.E., Wiseth R., Gullestad L., Aukrust P., Damås J.K. Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-STelevation myocardial infarction. Int J Cardiol. 2018; 271:1-7. doi:10.1016/j.ijcard.2018.04.136.; Provan S.A., Berg I.J., Hammer H.B., Mathiessen A., Kvien T.K., Semb A.G. The impact of newer biological disease modifying antirheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tociliziumab. PLoS One 2015; 10:e0130709. doi:10.1371/journal.pone.0130709.; van Vollenhoven R.F., Emery P., Bingham C.O. 3rd, Keystone E.C., Fleischmann R.M., Furst D.E., Tyson N., Collinson N., Lehane P.B. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013; 72(9):1496-502. doi:10.1136/annrheumdis-2012-201956.; Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., Fonseca F., Nicolau J., Koenig W., Anker S.D., Kastelein J.J.P., Cornel J.H., Pais P., Pella D., Genest J., Cifkova R., Lorenzatti A., Forster T., Kobalava Z., Vida-Simiti L., Flather M., Shimokawa H., Ogawa H., Dellborg M., Rossi P.R.F., Troquay R.P.T., Libby P., Glynn R.J.; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. doi:10.1056/NEJMoa1707914.; Ikonomidis I., Tzortzis S., Andreadou I., Paraskevaidis I., Katseli C., Katsimbri P., Pavlidis G., Parissis J., Kremastinos D., Anastasiou-Nana M., Lekakis J. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014; 7(4):619-28. doi:10.1161/CIRCIMAGING.113.001193.; Ambrosino P., Tasso M., Lupoli R., Di Minno A., Baldassarre D., Tremoli E., Di Minno M.N. Noninvasive assessment of arterial stiffness in patients with rheumatoid arthritis: a systematic review and meta-analysis of literature studies. Ann Med. 2015; 47(6):457-67. doi:10.3109/07853890.2015.1068950.; Ikdahl E., Rollefstad S., Wibetoe G., Olsen I.C., Berg I.J., Hisdal J., Uhlig T., Haugeberg G., Kvien T.K., Provan S.A., Semb A.G. Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis. J Rheumatol. 2016; 43(9):1622-30. doi:10.3899/jrheum.160053.; Corrales A., González-Juanatey C., Peiró M.E., Blanco R., Llorca J., González-Gay M.A. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis. 2014; 73(4):722-7. doi:10.1136/annrheumdis-2012-203101.; Hodge J.A., Kawabata T.T., Krishnaswami S., Clark J.D., Telliez J.B., Dowty M.E., Menon S., Lamba M., Zwillich S. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(2):318-28.; Дамъянов Н., Князева Л.И., Князева Л.А., Горяйнов И.И., Мещерина Н.С., Степченко М.А., Хардикова Е.М., Понкратов В.И., Рудаков О.С., Бобынцев Я.И., Шунин Е.М., Овсянников Н.И. Влияние тофацитиниба на вазомоторную функцию эндотелия и артериальную ригидность у больных ревматоидным артритом. Курский научно-практический вестник «Человек и его здоровье». 2018;(4):37-44. doi:10.21626/vestnik/2018-4/06.; Tanaka Y., Suzuki M., Nakamura H., Toyoizumi S., Zwillich S.H.; Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011; 63(8):1150-8. doi:10.1002/acr.20494.; Charles-Schoeman C., DeMasi R., Valdez H., Soma K., Hwang L.J., Boy M.G., Biswas P., McInnes I.B. Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71(9):1450-1459. doi:10.1002/art.40911.; Taylor P.C., Weinblatt M.E., Burmester G.R., Rooney T.P., Witt S., Walls C.D., Issa M., Salinas C.A., Saifan C., Zhang X., Cardoso A., González-Gay M.A., Takeuchi T. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71(7):1042-1055. doi:10.1002/art.40841.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/1245
https://doi.org/10.17802/2306-1278-2022-11-4-105-117

Comorbid infections in patients with spondyloarthritis who received modern antirheumatic therapy (preliminary data) ; Коморбидные инфекции у больных спондилоартритами, получающих современную антиревматическую терапию (предварительные данные)

Συγγραφείς: M. M. Baranova, N. V. Muravyeva, B. S. Belov, S. I. Glukhova, T. V. Korotaeva, М. М. Баранова, Н. В. Муравьева, Б. С. Белов, С. И. Глухова, Т. В. Коротаева

Συνεισφορές: Статья подготовлена в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой». № государственного задания 1021051503137-7.

Πηγή: Rheumatology Science and Practice; Vol 60, No 4 (2022); 455-459 ; Научно-практическая ревматология; Vol 60, No 4 (2022); 455-459 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: вакцинация, serious comorbid infections, respiratory tract and ENT infections, herpes virus infections, mycoses, immunoinflammatory rheumatic diseases, spondyloarthritis, biological drugs, basic anti-inflammatory drugs, vaccination, серьезные коморбидные инфекции, инфекции дыхательных путей и ЛОР-органов, герпес-вирусные инфекции, микозы, иммуновоспалительные ревматические заболевания, спондилоартриты, генно-инженерные биологические препараты, базисные противовоспалительные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3199/2213; Minozzi S, Bonovas S, Lytras T, Pecoraro V, González-Lorenzo M, Bastiampillai AJ, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: A systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(Suppl 1):11-34. doi:10.1080/14740338.2016.1240783; Atzeni F, Sarzi-Puttini P, Sebastiani M, Panetta V, Salaffi F, Iannone F, et al.; GISEA group. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: A survey from the Italian registry GISEA. Clin Exp Rheumatol. 2019;37(4):649-655.; Lim DH, Kim YJ, Kim SO, Hong S, Lee CK, Yoo B, et al. The risk of herpes zoster in patients with ankylosing spondylitis: Analysis of the Korean National Health Insurance Service – Sample cohort database. Mod Rheumatol. 2018;28(1):168-173. doi : 10.1080/14397595.2017.1325034; de Vries MK, Arkema EV, Jonsson J, Bruchfeld J, Jacobsson LTH, Askling J; ARTIS Study Group. Tuberculosis risk in ankylosing spondylitis, other spondyloarthritis, and psoriatic Arthritis in Sweden: A population-based cohort study. Arthritis Care Res (Hoboken). 2018;70(10):1563-1567. doi:10.1002/acr.23487; Aydin V, Akici A, Isli F, Aksoy M, Aydin M, Gursoz H. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study. J Clin Pharm Ther. 2019;44(4):553-560. doi:10.1111/jcpt.12814; Муравьева НВ, Белов БС, Баранова ММ, Коротаева ТВ. Коморбидные инфекции при спондилоартритах: современный взгляд на проблему. Современная ревматология. 2020; 14(4):103-110. doi:10.14412/1996-7012-2020-4-103-110; Баранова ММ, Муравьева НВ, Белов БС. Частота и структура коморбидных инфекций у больных спондилоартритами (предварительные данные). Медицинский совет. 2021;2:122- 126. doi:10.21518/2079-701X-2021-2-122-126; Wallis D, Thavaneswaran A, Haroon N, Ayearst R, Inman RD. Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: Results from a longitudinal observational cohort. Rheumatology (Oxford). 2015;54(1):152-156. doi:10.1093/rheumatology/keu255; Combe B, Rahman P, Kameda H, Cañete JD, Gallo G, Agada N, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22(1):14. doi:10.1186/s13075-020-2099-0; Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L, Descalzo MA, Gómez-Reino JJ; BIOBADASER Study Group. Infections in patients treated with tumor necrosis factor antagonists: Incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011;137(12):533-540. doi:10.1016/j.medcli.2010.11.032; Баранова ММ, Муравьева НВ, Белов БС, Черкасова МВ, Верижникова ЖГ, Коротаева ТВ. Иммуногенность, безопасность и клиническая эффективность 23-валентной пневмококковой полисахаридной вакцины у больных спондилоартритами (предварительные данные). Антибиотики и химиотерапия. 2022;67(1-2):39-44. doi:10.37489/0235-2990-2022-67-1-2-39-44; Буханова ДВ, Белов БС, Тарасова ГМ, Эрдес Ш, Дубинина ТВ, Лукина ГВ, и др. Эффективность, безопасность и иммуногенность трехвалентной инактивированной сплит-вакцины против гриппа у пациентов с ревматическими заболеваниями. Медицинский совет. 2018,12:106-110. doi:10.37489/0235-2990-2022-67-1-2-39-44; Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi:10.1136/annrheumdis-2019-215882; Aikawa NE, Rosa DT, Del Negro GM, Moraes JC, Ribeiro AC, Saad CG, et al. Systemic and localized infection by Candida species in patients with rheumatic diseases receiving anti-TNF therapy. Rev Bras Reumatol Engl Ed. 2016;56(6):478-482. doi:10.1016/j.rbre.2015.08.004; Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47-62. doi:10.1111/bjd.15015; Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al.; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis – Results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. doi:10.1056/NEJMoa1314258; Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, et al. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung. 2013;191(5):565-571. doi:10.1007/s00408-013-9481-5

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3199
https://doi.org/10.47360/1995-4484-2022-455-459

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look ; Труднолечимый ревматоидный артрит (difficult-to-treat RA) в клинической практике ревматологического стационара. Первый взгляд

Συγγραφείς: A. V. Gordeev, E. V. Matyanova, Yu. A. Olyunin, E. A. Galushko, E. G. Zotkin, А. В. Гордеев, Е. В. Матьянова, Ю. А. Олюнин, Е. А. Галушко, Е. Г. Зоткин

Πηγή: Modern Rheumatology Journal; Том 16, № 2 (2022); 13-20 ; Современная ревматология; Том 16, № 2 (2022); 13-20 ; 2310-158X ; 1996-7012

Θεματικοί όροι: мультиморбидность, treatment, difficult-to-treat rheumatoid arthritis, biologic disease modifying antirheumatic drugs, glucocorticoids, disease modifying antirheumatic drugs, multimorbidity, лечение, труднолечимый ревматоидный артрит, генно-инженерные биологические препараты, глюкокортикоиды, базисные противовоспалительные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1269/1223; Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические заболевания – проблемы иммунопатологии и персонифицированной терапии. Вестник Российской академии медицинских наук. 2015;70(2):169-82.; Эрдес ШФ, Галушко ЕА. Медико-социальное значение патологии суставов и позвоночника среди взрослого населения РФ. Боль. 2009;(3):19.; Насонов ЕЛ, Лила АМ. Эффективность и безопасность упадацитиниба при ревматоидном артрите. Научно-практическая ревматология. 2020;58(5):532-43.; Котовская МА, Никишина НЮ, Олюнин ЮА. Стратегия снижения дозы и отмены генно-инженерных биологических препаратов при ревматоидном артрите в стадии ремиссии. Научно-практическая ревматология. 2018;56(1):99-106.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020. 448 с.; Насонов ЕЛ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место глюкокортикоидов. Научно-практическая ревматология. 2015;53(3): 238-50.; Лила АМ, Олюнин ЮА, Гордеев АВ. Оценка статуса больных ревматоидным артритом. Современные тенденции. Современная ревматология. 2020;14(2):7-13.; Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3): 263-71.; Гордеев АВ, Олюнин ЮА, Галушко ЕА и др. Труднолечимый ревматоидный артрит. Какой он? Современная ревматология. 2021;15(5):7-11.; Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31-5. doi:10.1136/annrheumdis-2020-217344.; Насонов ЕЛ, Лила АМ, Мазуров ВИ и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-54.; Messelink MA, Roodenrijs NMT, van Es B, et al. Identification and prediction of difficultto-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon. Arthritis Res Ther. 2021 Jul 8;23(1):184. doi:10.1186/s13075-021-02560-5.; Watanabe R, Hashimoto M, Murata K, et al. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort. Immunol Med. 2021 May 25:1-10. doi:10.1080/25785826.2021.1928383; Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-totreat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021 Nov 3;60(11):5247-56. doi:10.1093/rheumatology/keab209; Roodenrijs NMT, van der Goes MC, Welsing PMJ, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology (Oxford). 2021 Aug 2; 60(8):3778-88. doi:10.1093/rheumatology/keaa860.; Roodenrijs NMT, van der Goes MC, Welsing PMJ, et al. Non-adherence in difficultto-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study. Rheumatology (Oxford). 2021 Nov 3;60(11):5105-16. doi:10.1093/rheumatology/keab130.; Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Jul; 73(7):1108-23. doi:10.1002/art.41752.; Smolen JS, Landewй RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685-99. doi:10.1136/annrheumdis-2019-216655.; Benham H, Chiu H, Tesiram J, et al. A patient-centered knowledge translation tool for treat-to-target strategy in rheumatoid arthritis: Patient and rheumatologist perspectives. Int J Rheum Dis. 2021 Mar;24(3):355-63. doi:10.1111/1756-185X.14051.; Batko B, Batko K, Krzanowski M, Zuber Z. Physician Adherence to Treat-to-Target and Practice Guidelines in Rheumatoid Arthritis. J Clin Med. 2019 Sep 8;8(9):1416. doi:10.3390/jcm8091416.; Лила АМ, Гордеев АВ, Олюнин ЮА, Галушко ЕА. Мультиморбидность в ревматологии. От комплексной оценки болезни – к оценке комплекса болезней. Современная ревматология. 2019;13(3):4-9.; Фоломеева ОМ, Насонов ЕЛ, Андрианова ИА и др. Оценка функционального состояния популяции российских больных ревматоидным артритом по данным исследования RAISER. Научно-практическая ревматология. 2010;48(3):15-22.; Cai YM, Li R, Ye H, et al. Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study. Chin Med J (Engl). 2020 Jun 20;133(12):1397-403. doi:10.1097/CM9.0000000000000811.; Nekvindova L, Vencovsky J, Pavelka K, et al. Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. Arthritis Res Ther. 2021 Jan 6;23(1):11. doi:10.1186/s13075-020-02393-8.; Harrold LR, Reed GW, John A, et al. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-87. doi:10.1002/acr.23294.; Каратеев ДЕ, Лучихина ЕЛ, Демидова НВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА): результаты лечения 130 больных в течение 12 месяцев. Научно-практическая ревматология. 2014;52(6):607-14.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1269
https://doi.org/10.14412/1996-7012-2022-2-13-20

Chronic Heart Failure in Rheumatoid Arthritis Patients (Part III): Effects of Antirheumatic Drugs ; Хроническая сердечная недостаточность у больных ревматоидным артритом (часть III): влияние противоревматической терапии

Συγγραφείς: D. Novikova S., H. Udachkina V., I. Kirillova G., T. Popkova V., Д. Новикова С., Е. Удачкина В., И. Кириллова Г., Т. Попкова В.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 15, No 6 (2019); 820-830 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 6 (2019); 820-830 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: rheumatoid arthritis, chronic heart failure, conventional synthetic disease-modifying anti-rheumatic drugs, targeted conventional synthetic disease-modifying anti-rheumatic drugs, biological disease-modifying anti-rheumatic drugs, cardiac function, N-terminal prohormone of brain natriuretic peptide, ревматоидный артрит, хроническая сердечная недостаточность, синтетические базисные противовоспалительные препараты, таргетные синтетические базисные противовоспалительные препараты, генно-инженерные биологические препараты, функция сердца, N-концевой предшественник мозгового натрийуретического пептида

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2074/1889; Новикова Д.С., Кириллова И.Г., Удачкина Е.В., Попкова Т.В. Хроническая сердечная недостаточность у больных ревматоидным артритом (часть 1): распространенность, особенности этиологии и патогенеза. Рациональная Фармакотерапия в Кардиологии. 2018;14(5):703-10. DOI:10.20996/1819-6446-2018-14-5-703-710.; Новикова Д.С., Удачкина Е.В., Кириллова И.Г., Попкова Т.В. Хроническая сердечная недостаточность у больных ревматоидным артритом (часть II): трудности диагностики. Рациональная Фармакотерапия в Кардиологии. 2018;14(6):870-8. DOI:10.20996/18196446-2018-14-6-870-878.; Ridker P.M., Everett B.M., Thuren T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119-31. DOI:10.1056/NEJMoa1707914.; Zhang Y., Lu N., Peloquin C., et al. Improved survival in rheumatoidarthritis: a general population-based cohort study. Ann Rheum Dis. 2017;76(2):408-13. DOI:10.1136/annrheumdis-2015-209058.; Kerola A.M., Nieminen T.V., Virta L.J., et al. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008. Clin Exp Rheumatol. 2015; 33(3):391-8. PMID: 25936374.; Solomon D.H., Reed G.W., Kremer J.M., et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67:1449-55. DOI:10.1002/art.39098.; Logstrup B.B., Ellingsen T., Pedersen A.B., et al. Development of heart failure in patients with rheumatoid arthritis: A Danish population-based study. Eur J Clin Invest. 2018;48(5):e12915. DOI:10.1111/eci.12915.; Arts E.E., Fransen J., denBroeder A.A., et al. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. Ann Rheum Dis. 2017;76(10):1693-9. DOI:10.1136/annrheumdis-2016-210997.; Bradham W., Ormseth M.J., Elumogo C., et al. Absence of fibrosis and inflammation by cardiac magnetic resonance imaging in rheumatoid arthritis patients with low to moderate disease activity. J Rheumatol. 2018;45(8):1078-84. DOI:10.3899/jrheum.170770.; Popkova T.V., Novikova D.S., Gasparyan A.Y., Nasonov E.L. Cardiovascular effects of methotrexate in rheumatoid arthritis revisited. Curr Med Chem. 2015;22(16):1903-10. PMID:25876749. DOI:10.2174/0929867322666150415122039.; Roubille C., Richer V., Starnino T., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74(3):480-9. DOI:10.1136/annrheumdis-2014-206624.; Ridker P.M., Everett B.M., Pradhan A., et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019;21;380(8):752-2. DOI:10.1056/NEJMoa1809798.; Zhang Z., Zhao P., Li A., et al. Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. Mediators Inflamm. 2009;2009:389720. DOI:10.1155/2009/389720.; Li W., Gong K., Ding Y., et al. Effects of triptolide and methotrexate nanosuspensions on left ventricular remodeling in autoimmune myocarditis rats. Int J Nanomedicine. 2019;14:851-63. DOI:10.2147/IJN.S191267.; Campochiaro C., De Luca G., Sartorelli S., et al. Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. J ClinRheumatol 2018; [Epub ahead of print]. DOI:10.1097/RHU.0000000000000897.; Gong K., Zhang Z., Sun X., et al. The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. Am Heart J. 2006;151(1):62-8. DOI:10.1016/j.ahj.2005.02.040.; Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005;44(5):677-80. DOI:10.1093/rheumatology/keh610.; Myasoedova E., Crowson C.S., Nicola P.J., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol. 2011;38(8):1601-6. DOI:10.3899/jrheum.100979.; Logstrup B.B., Masic D., Laurbjerg T.B., et al. Left ventricular function at two-year follow-up in treatmentnaive rheumatoid arthritis patients is associated with anti-cyclic citrullinated peptide antibody status: a cohort study. Scand J Rheumatol. 2017;46(6):432-40. DOI:10.1080/03009742.2016.1249941.; Baker J.F., Sauer B., Teng C.C., et al. Initiation of disease-modifying therapies in rheumatoid arthritis is associated with changes in blood pressure. J Clin Rheumatol. 2018;24(4):203-209. DOI:10.1097/RHU.0000000000000736.; Mangoni A.A., Baghdadi L.R., Shanahan E.M., et al. Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Ther Adv Musculoskel Dis. 2017;9(9):213-29. DOI:10.1177/1759720X17719850.; Gasparyan A.Y., Ayvazyan L., Cocco G., Kitas G.D. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des. 2012;18(11):1543-55. DOI:10.2174/138161212799504759.; Minoretti P., Bruno A., Di Vito C., Emanuele E. Leflunomide as an antiatherogenic drug. Med Hypotheses. 2007;68(5):1175-6. DOI:10.1016/j.mehy.2006.10.036.; Nielsen C.B., Nielsen C., Nybo M., et al. The in vitro effect of antirheumatic drugs on platelet function. Platelets. 2019;2:1-10. DOI:10.1080/09537104.2019.1609665.; Ma Z.G., Zhang X., Yuan Y.P., et al. A77 1726 (leflunomide) blocks and reverses cardiac hypertrophy and fibrosis in mice. Clin Sci (Lond.) 2018;132:685-99. DOI:10.1042/CS20180160.; Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum. 2006;55:531-6. DOI:10.1002/art.22094.; Naranjo A., Sokka T., Descalzo M.A., et al.; f-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008;10(2):R30. DOI:10.1186/ar2383.; Solomon D.H., Avorn J., Katz J.N. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3790-8. DOI:10.1002/art.22255.; Serelis J., Panagiotakos D.B., Mavrommati M., Skopouli F.N. Cardioascular disease is related to hypertension in patients with RA: a greek cohort study. J Rheumatol. 2011;38(2):236-41. DOI:10.3899/jrheum.100564.; Новикова Д.С., Попкова Т.В., Герасимов А.Н. и др. Высокая частота сердечных сокращений как потенциальный фактор риска развития сердечно-сосудистых заболеваний у женщин с ревматоидным артритом. Рациональная Фармакотерапия в Кардиологии. 2012;8(5):636-46. DOI:10.20996/1819-6446-2012-8-5-636-646.; Coirier V., Lescoat A., Chabanne C., et al. Pulmonary arterial hypertension in four patients treated by leflunomide. Joint Bone Spine. 2018;85(6):761-3. DOI:10.1016/j.jbspin.2017.12.014.; Rempenault C., Combe B., Barnetche T., et al. Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res. 2019; [Epub ahead of print]. DOI:10.1002/acr.23826.; Rempenault C., Combe B., Barnetche T., et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018;77(1):98-103. DOI:10.1136/annrheumdis-2017-211836.; Liu D., Li X., Zhang Y., et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Design, Development and Therapy. 2018;11;12:1685-95. DOI:10.2147/DDDT.S166893.; Chatre C., Roubille F., Vernhet H., et al. Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature Drug Saf. 2018;41(10):919-31. DOI:10.1007/s40264-018-0689-4.; Baniaamam M., Paulus W.J., Blanken A.B., Nurmohamed M.T. The effect of biological DMARDs on the risk of congestive heart failure in rheumatoid arthritis: a systematic review. Expert Opin Biol Ther. 2018;18(5):585-94. DOI:10.1080/14712598.2018.1462794.; Kotyla P.J. Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure? Int J Mol Sci. 2018;12;19(6). pii:E1739. DOI:10.3390/ijms19061739.; Hartman M.H.T., Groot H.E., Leach I.M., et al. Trends Cardiovasc Med. 2018l;28(6):369-79. DOI:10.1016/j.tcm.2018.02.003.; Pascale V., Finelli R., Giannotti R., et al. Cardiac eccentric remodeling in patients with rheumatoid arthritis. Sci Rep. 2018;8(1):5867. DOI:10.1038/s41598-018-24323-0.; Ntusi N.A.B., Francis J.M., Sever E., et al. Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. Int J Cardiol. 2018;270:253-59. DOI:10.1016/j.ijcard.2018.06.099.; Mann D.L., McMurray J.J., Packer M., et al. Targeted anti cytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-602. DOI:10.1161/01.CIR.0000124490.27666.B2.; Chung E.S., Packer M., Lo K.H., et al. Anti-TNF therapy against congestive heart failure investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-40. DOI:10.1161/01.CIR.0000077913.60364.D2.; Setoguchi S., Schneeweiss S., Avorn J., et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008;156(2):336-41. DOI:10.1016/j.ahj.2008.02.025.; Curtis J.R., Kramer J.M., Martin C., et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford). 2007;46(11):168893. DOI:10.1093/rheumatology/kem212.; Santos R.C., Figueiredo V.N., Martins L.C., et al. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Rev Assoc Med Bras. 2012;58(6):698-702.; Al-Aly Z., Pan H., Zeringue A., et al. Tumor necrosis factor-αblockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Translational Research. 2011;157(1):10-8. DOI:10.1016/j.trsl.2010.09.005.; Jensen T.B., Tsao N., Pawar A., et al. Risk of heart failure following exposure to non-TNFi compared to TNFi biologics in us patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78 suppl. 2:A1392. DOI:10.1136/annrheumdis-2019-eular.1384; Schau T., Gottwald M., Arbach O., et al. Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J Rheumatol. 2015;42(11):2029-37. DOI:10.3899/jrheum.141647.; Solomon D.H., Rassen J.A., Kuriya B., et al. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2013;72:1813-8. DOI:10.1136/annrheumdis-2012-202136.; Tomaš L., Lazurova I., Oetterova M., et al. Left ventricular morphology and function in patients with rheumatoid arthritis. Wien Klin Wochenschr. 2013;125(9-10):233-8. DOI:10.1007/s00508-0130349-8.; Vizzardi E., Cavazzana I., Franceschini F. Left ventricular function in rheumatoid arthritis during anti-TNF-treatment: a speckle tracking prospective echocardiographic study Monaldi Arch Chest Dis. 2016;84(1-2):716. DOI:10.4081/monaldi.2015.716.; Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of antitumor necrosis factor therapy. 2004;116(5):305-11. DOI:10.1016/j.amjmed.2003.09.039; Morgan C.L., Emery P., Porter D., et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: Long-term safety and survival using prospective, observational data. Rheumatology. 2014;53(1):186-94. DOI:10.1093/rheumatology/ket333.; Peters M.J.L., Welsh P., McInnes I.B., et al. Tumour necrosis factor α blockade reduces circulating Nterminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: Results from a prospective cohort study. Ann Rheum Dis. 2010;69(7):1281-85. DOI:10.1136/ard.2009.119412; Kotyla P.J., Owczarek A., Rakoczy J., et al. Infliximab treatment increases left ventricular ejection fraction in patientswith rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol. 2012;39:701-6.; Cetin S., Mustafa G.V., Goksal K., et al. Infliximab, an anti-TNF-alpha agent, improves left atrial abnormalities in patients with rheumatoid arthritis: preliminary results. Cardiovasc J Afr. 2014;25(4):168-75.; Amigues I., Tugcu A., Russo C., et al. Myocardial inflammation, measured using 18-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) is associated with disease activity in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(4):496-506. DOI:10.1002/art.40771.; Giles J.T., Malayeri A.A., Fernades V., et al. Left ventricular Structure and Function in Patients With Rheumatoid Arthritis, As Assessed by Cardiac Magnetic Resonance Imaging. Arthritis and Rheumatism. 2010;62(4):940-51. DOI:10.1002/art.27349.; Ikonomidis I., Lekakis J.P., Nikolaou M., et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117:2662-9. DOI:10.1161/CIRCULATIONAHA.107.731877.; Ikonomidis I., Tzortzis S., Andreadou I., et al. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7:619-28. DOI:10.1161/CIRCIMAGING.113.001193.; Van Tassell B.W., Arena R., Biondi-Zoccai G., et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the DHART pilot study). Am J Cardiol. 2014;113:321-7. DOI:10.1016/j.amjcard.2013.08.047.; VanTassell B.W., Canada J., Carbone S., et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail. 2017;10(11): PII:e004373. DOI:10.1161/CIRCHEARTFAILURE.117.004373.; Ikonomidis I., Pavlidis G., Katsimbri P. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clin Res Cardiol. 2019;108(10):1093-101. DOI:10.1007/s00392-019-01443-9.; Abbate A., Canada J.M., Van Tassell B.W., et al. A Interleukin-1 blockade in rheumatoid arthritis and heart failure: A missed opportunity? Int J Cardiol. 2014;171(3):e125-6. DOI:10.1016/j.ijcard.2013.12.078.; De Luca G., Campochiaro C., Cavalli G., et al. Efficacy and safety of anakinra in the treatment of autoimmune myocarditis Ann Rheum Dis. 2019;78 suppl 2:A576. DOI:10.1136/annrheumdis-2019eular.3067.; Abbate A. Interleukin-1b lockade with canakinumab to improve exercise capacity in patients with chronic systolic heart failure and elevated high sensitivity c-reactive protein (Hs-CRP). [cited by Sep 20, 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT01900600.; Yokoe I., Kobayashi H., Kobayashi Y., et al. Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol. 2018;47(5):364-70. DOI:10.1080/03009742.2017.1418424.; Generali E., Carrara C., Selmi G., et. al. Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept. Clinical and Experimental Rheumatology. 2018;36:310-3.; Xie F., Yun H., Levitan E.B., et al. Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2019;71(8):1004-1018. DOI:10.1002/acr.23737.; Kobayashi H., Kobayashi Y., Giles J.T., et al. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging. J Rheumatol. 2014;41(10):1916-21. DOI:10.3899/jrheum.131540.; Kobayashi Y., Kobayashi H., Giles J., et al. Takei Impact of biological treatment on left ventricular function and morphology in rheumatoid arthritis patients without cardiac symptoms, assessed by cardiac magnetic resonance imaging. Scand J Rheumatol. 2016;1-2 DOI:10.3109/03009742.2016.1173722; Welsh P., Tuckwell K., McInnes I.B., Sattar N. Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis. 2016;254:167-71. DOI:10.1016/j.atherosclerosis.2016.10.016.; Suzuki A., Tamamura T., Okai T. Five-year administration of tocilizumab to a patient with rheumatoid arthritis complicated by severe chronic heart failure. Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(6):488-92. DOI:10.2177/jsci.37.488.; Nevers T., Salvador A.M., Grodecki-Pena A., et al. Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail. 2015;8(4):776-87. DOI:10.1161/CIRCHEARTFAILURE.115.002225.; Kallikourdis M., Martini E., Carullo P. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat Commun. 2017;8:14680. DOI:10.1038/ncomms14680.; Generali E., Carrara G., Kallikourdis M., et al. Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatol Int. 2019;39(2):239-43. DOI:10.1007/s00296-018-4196-9.; Jin Y., Kang E.H., Brill G., et al. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. J Rheumatol. 2018;45(9):1240-8. DOI:10.3899/jrheum.170926.; Novikova D.S., Popkova T.V., Nasonov E.L. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Curr Pharm Des. 2012;18:1512-8. DOI:10.2174/138161212799504768.; Novikova D.S., Popkova T.V., Lukina G.V., et al. The effects of rituximab on lipids, arterial stiffness and carotid Intima-media thickness in rheumatoid arthritis. J Korean Med Sci, 2016;31(2):202-7. DOI:10.3346/jkms.2016.31.2.202.; Sanchez-Trujillo L., Jerjes-Sanchez C., Rodriguez D., et al. Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients withheart failure with reduced ejection fraction, ICFEr-RITU2: study protocol. BMJ Open. 2019;9:e022826. DOI:10.1136/bmjopen-2018022826.; Youker K.A., Assad-Kottner C., Cordero-Reyes A.M., et al. High proportion of patients with endstage heart failure regardless of aetiology demonstrates anti-cardiac antibody deposition in failing myocardium: humoral activation, a potential contributor of disease progression. Eur Heart J. 2014;35:1061-8. DOI:10.1093/eurheartj/eht506.; Sanchez-Trujillo L., Vazquez-Garza E., Castillo E.C., et al. Role of adaptive immunity in the development and progression of heart failure: new evidence. Arch Med Res. 2017;48:1-11. DOI:10.1016/j.arcmed.2016.12.008.; Lee S. Safe Use of Rituximab in an Elderly Patient With Rheumatoid Arthritis and Severe Heart Failure A Case Report. J Clin Rheumatol. 2018;24(3):167-9.; Charles-Schoeman C., Wicker P., Gonzalez-Gay M.A., et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46(3):261-71. DOI:10.1016/j.semarthrit.2016.05.014.; Kremer J., Bingham C., Cappelli L., et al. Post-approval comparative safety study of tofacitinib and biologic DMARDS: five-year results from a US-based rheumatoid arthritis registry Ann Rheum Dis. 2019;78 suppl 2:A82. DOI:10.1136/annrheumdis-2019-eular.621.; Novikova D.S., Udachkina H.V., Markelova E.I., et al. Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatol Int. 2019;39(7):1181-9. DOI:10.1007/s00296-019-04303-x.; Novikova D., Kirillova I., Markelova E., et al. The first report of significantly improvement of NT-proBNP level in rheumatoid arthritis patients treated with tofacitinib during 12-month follow-up. Ann Rheum Dis. 2019;78 suppl 2:pA368. DOI:10.1136/annrheumdis-2019-eular.2865.; Taylor P.C., Weinblatt M.E., Burmester G.R., et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(7):1042-55. DOI:10.1002/art.40841.; https://www.rpcardio.com/jour/article/view/2074

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2074
https://doi.org/10.20996/1819-6446-2019-15-6-820-830

Возможности отмены противовоспалительной базисной терапии у пациентов с ювенильным идиопатическим артритом на фоне длительной лекарственной ремиссии ; The possibility of discontinuation of anti-inflammatory basic therapy in patients with juvenile idiopathic arthritis against the background of long-term drug remission

Συγγραφείς: Brook, Ya. A., Trunova, Yu. A., Брук, Я. А., Трунова, Ю. А.

Πηγή: Сборник статей

Θεματικοί όροι: JUVENILE IDIOPATHIC ARTHRITIS, BASIC ANTI-INFLAMMATORY DRUGS, DRUG-FREE REMISSION, ЮВЕНИЛЬНЫЙ ИДИОПАТИЧЕСКИЙ АРТРИТ, БАЗИСНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ, БЕЗЛЕКАРСТВЕННАЯ РЕМИССИЯ

Περιγραφή αρχείου: application/pdf

Relation: Актуальные вопросы детской кардиологии и ревматологии: материалы Юбилейной научно-практической конференции Городского детского кардиоревматологического центра ГАУЗ СО «ДГКБ № 11» (29–30 октября 2021 года, в комбинированном формате, Екатеринбург, Россия) / под ред. С. А. Царьковой. – Екатеринбург : ИЗДАТЕЛЬСТВО АМБ, 2021. – 116 с.; http://elib.usma.ru/handle/usma/4788

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/4788

Antirheumatic drugs and COVID-19: frustrations and hopes ; Противоревматические препараты и COVID-19: разочарования и надежды

Συγγραφείς: E. S. Aronova, B. S. Belov, Е. С. Аронова, Б. С. Белов

Πηγή: Meditsinskiy sovet = Medical Council; № 10 (2021); 134-139 ; Медицинский Совет; № 10 (2021); 134-139 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: барицитиниб, SARS-CoV-2, DMARDs, hydroxychloroquine, glucocorticoids, tocilizumab, baricitinib, базисные противовоспалительные препараты, гидроксихлорохин, глюкокортикоиды, тоцилизумаб

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6275/5689; Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G. et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787-1799. https://doi.org/10.1056/NEJMoa2001282.; Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C. et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383:1813-1826. https://doi.org/10.1056/NEJMoa2007764.; Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V., Abdool Karim Q. et al. Repurposed antiviral drugs for Covid-19 - interim who solidarity trial results. N Engl J Med. 2021;384:497-511. https://doi.org/10.1056/NEJMoa2023184.; Devaux C.A., Rolain J.-M., Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938. https://doi.org/10.1016/j.ijantimi-cag.2020.105938.; Mitja O., Corbacho-Monne M., Ubals M., Tebe C., Penafiel J., Tobias A. et al. Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial. Clin Infect Dis. 2020;ciaa100. https://doi.org/10.1093/cid/ciaa1009.; Skipper C.P, Pastick K.A., Engen N.W., Bangdiwala A.S., Abassi M., Lofgren S.M. et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020;173(8):623-631. https://doi.org/10.7326/M20-4207.; Abd-Elsalam S., Esmail E.S., Khalaf M., Abdo E.F., Medhat M.A., Abd El. et al. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. Am J Trop Med Hyg. 2020;103(4):1635-1639. https://doi.org/10.4269/ajtmh.20-0873.; Lyngbakken M.N., Berdal J.E., Eskesen A., Kvale D., Olsen I.C., Rangberg A. et al. Norwegian coronavirus disease 2019 (NO COVID-19) pragmatic open label study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):485. https://doi.org/10.1186/s13063-020-04420-0.; Horby P, Mafham M., Linsell L., Bell J.L., Staplin N., Emberson J.R. et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030-2040. https://doi.org/10.1056/NEJMoa2022926.; Cavalcanti A.B., Zampieri F.G., Rosa R.G., Azevedo L.C.P, Veiga V.C., Avezum A. et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020;383:2041-2052. https://doi.org/10.1056/NEJMoa2019014.; Huang H.D., Jneid H., Aziz M., Ravi V., Sharma PS., Larsen T. et al. Safety and effectiveness of hydroxychloroquine and azithromycin combination therapy for treatment of hospitalized patients with COVID-19: a Propensity-Matched study. Cardiol Their. 2020;9:523-534. https://doi.org/10.1007/s40119-020-00201-7.; Tang W., Cao Z., Han M., Wang Z., Chen J., Sun W. et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. https://doi.org/10.1136/bmj.m1849.; Horby P, Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L. et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2021;384:693-704. https://doi.org/10.1056/NEJMoa2021436.; Tomazini B.M., Maia I.S., Cavalcanti A.B., Berwanger O., Rosa R.G., Veiga V.C. et al. Effect of dexamethasone on days alive and Ventilator-Free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the Codex randomized clinical trial. JAMA. 2020;324(13):1307. https://doi.org/10.1001/jama.2020.17021.; Jeronimo C.M.P., Farias M.E.L., Val F.F.A., Sampaio V.S., Alexandre M.A.A., Melo G.C. et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021;72(9):e373-e381. https://doi.org/10.1093/cid/ciaa1177.; Edalatifard M., Akhtari M., Salehi M., Naderi Z., Jamshidi A., Mostafaei S. et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56:2002808. https://doi.org/10.1183/13993003.02808-2020.; Angus D.C., Berry S., Lewis RJ., Al-Beidh F., Arabi Y., van Bentum-Puijk W. et al. The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. Rationale and design. Ann Am Thorac Soc. 2020;17(7):879-891. https://doi.org/10.1513/AnnalsATS.202003-192SD.; Dequin P.F., Heming N., Meziani F., Plantefeve G., Voiriot G., Badie J. et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298-1306. https://doi.org/10.1001/jama.2020.16761.; Tomazini B.M., Maia I.S., Cavalcanti A.B., Berwanger O., Rosa R.G., Veiga V.C. et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307-1316. https://doi.org/10.1001/jama.2020.17021.; Biran N., Ip A., Ahn J., Go R.C., Wang S., Mathura S. et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603-e612. https://doi.org/10.1016/S2665-9913(20)30277-0.; Somers E.C., Eschenauer G.A., Troost J.P., Golob J.L., Gandhi T.N., Wang L. et al. Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. Clin Infect Dis. 2020:ciaa954. https://doi.org/10.1093/cid/ciaa954.; Guaraldi G., Meschiari M., Cozzi-Lepri A., Milic J., Tonelli R., Menozzi M. et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474-e484. https://doi.org/10.1016/S2665-9913(20)30173-9.; Salama C., Han J., Yau L., Reiss W.G., Kramer B., Neidhart J.D. et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;384:20-30. https://doi.org/10.1056/NEJMoa2030340.; Hermine O., Mariette X., Tharaux P.L., Resche-Rigon M., Porcher R., Ravaud P. et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):32-40. https://doi.org/10.1001/jamain-ternmed.2020.6820.; Stone J.H., Frigault MJ., Serling-Boyd NJ., Fernandes A.D., Harvey L., Foulkes A.S. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333-2344. https://doi.org/10.1056/NEJMoa2028836.; Salvarani C., Dolci G., Massari M., Merlo D.F., Cavuto S., Savoldi L. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24-31. https://doi.org/10.1001/jamain-ternmed.2020.6615.; Gordon A.C., Mouncey P.R., AL-Beidh F., Rowan K.M., NichoL A.D. Arabi Y.M. et aL. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491-1502. https://doi.org/10.1056/NEJMoa2100433.; Gupta S., Wang W., Hayek S.S., Chan L., Mathews K.S., MeLamed M.L. et aL. Association between early treatment with tociLizumab and mortality among critically iLL patients with COVID-19. JAMA Intern Med. 2021;181(1):41-51. https://doi.org/10.1001/jamainternmed.2020.6252.; Fajgenbaum D.C., June C.H. Cytokine storm. N Engl J Med. 2020;383:2255-2273. https://doi.org/10.1056/NEJMra2026131.; Pasin L., CavaLLi G., NavaLesi P., SeLLa N., Landoni G., Yavorovskiy A.G. et aL. Anakinra for patients with COVID-19: a meta-anaLysis of non-randomized cohort studies. Eur J Intern Med. 2021;86:34-40. https://doi.org/10.1016/j.ejim.2021.01.016.; Richardson P., Griffin I., Tucker C., Smith D., OechsLe O., PheLan A. et aL. Baricitinib as potentiaL treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30-e31. https://doi.org/10.1016/S0140-6736(20)30304-4.; Stebbing J., PheLan A., Griffin I., Tucker C., OechsLe O., Smith D. et aL. COVID-19: combining antiviraL and anti-infLammatory treatments. Lancet Infect Dis. 2020;20:400-402. https://doi.org/10.1016/S1473-3099(20)30132-8.; Titanji B.K., FarLey M.M., Mehta A., Connor-SchuLer R., Moanna A., Cribbs S.K. et aL. Use of baricitinib in patients with moderate and severe COVID-19. Clin Infect Dis. 2021;72(7):1247-1250. https://doi.org/10.1093/cid/ciaa879.; Cantini F., NiccoLi L., Nannini C., Matarrese D., NataLe M.E.D., Lotti P. et aL. BeneficiaL impact of Baricitinib in COVID-19 moderate pneumonia; muLticentre study. J Infect. 2020;81(4):647-679. https://doi.org/10.1016/j.jinf.2020.06.052.; Rodriguez-Garcia J.L., Sanchez-Nievas G., ArevaLo-Serrano J., Garcia-Gomez C., Jimenez-Vizuete J.M., Martinez-ALfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observationaL cohort study. Rheumatology (Oxford). 2021;60(1): 399-407. https://doi.org/10.1093/rheumatoLogy/keaa587.; KaLiL A.C., Patterson T.F., Mehta A.K., Tomashek K.M., WoLfe C.R., Ghazaryan V. et aL. Baricitinib pLus remdesivir for hospitaLised aduLts with COVID-19. N Engl J Med. 2021;384:795-807. https://doi.org/10.1056/NEJMoa2031994.; ALunno A., Najm A., Machado P.M., Bertheussen H., Burmester G.R., Carubbi F. et aL. EULAR points to consider on pathophysioLogy and use of immunomoduLatory therapies in COVID-19. Ann Rheum Dis. 2021. https://doi.org/10.1136/annrheumdis-2020-219724.; D’SiLva K.M., SerLing-Boyd N., WaLLwork R., Hsu T., Fu X., GravaLLese E.M. et aL. CLinicaL characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US “hot spot”. Ann Rheum Dis. 2020;79(9):1156-1162. https://doi.org/10.1136/annrheumdis-2020-217888.; Mahase E. Covid-19: Anti-TNF drug adaLimumab to be triaLLed for patients in the community. BMJ. 2020;371:m3847. https://doi.org/10.1136/bmj.m3847.; Scarsi M., Piantoni S., CoLombo E., Airo P., Richini D., MicLini M. et aL. Association between treatment with coLchicine and improved survivaL in a singLe-centre cohort of aduLt hospitaLised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020;79(10):-1286-1289. https://doi.org/10.1136/annrheumdis-2020-217712.; Chen I.Y., Moriyama M., Chang M.F., Ichinohe T. Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 InfLammasome. Front. Microbiol. 2019;10:50. https://doi.org/10.3389/fmicb.2019.00050.; Brunetti L., Diawara O., Tsai A., Firestein B.L., Nahass R.G., Poiani G., SchLesinger N. CoLchicine to Weather the Cytokine Storm in HospitaLized Patients with COVID-19. J Clin Med. 2020;9(9):2961. https://doi.org/10.3390/jcm9092961.; Deftereos S.G., GiannopouLos G., Vrachatis D.A., Siasos G.D., Giotaki S.G., GargaLianos P. et aL. Effect of CoLchicine vs Standard Care on Cardiac and InfLammatory Biomarkers and CLinicaL Outcomes in Patients HospitaLized With Coronavirus Disease 2019: The GRECCO-19 Randomized CLinicaL TriaL. JAMA Netw Open. 2020;3(6):e2013136. https://doi.org/10.1001/jamanet-workopen.2020.13136.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/6275
https://doi.org/10.21518/2079-701X-2021-10-134-139

Achievement of minimal disease activity in psoriatic arthritis according to the time of administration of synthetic disease-modifying antirheumatic drugs, a comparative analysis of the efficacy of oral and subcutaneous methotrexate. Data from the All-Russian Psoriatic Arthritis Registry ; Достижение минимальной активности болезни при псориатическом артрите в зависимости от времени назначения синтетических базисных противовоспалительных препаратов, сравнительный анализ эффективности пероральной и подкожной форм метотрексата. Данные Общероссийского регистра пациентов с псориатическим артритом

Συγγραφείς: T. V. Korotaeva, E. Yu. Loginova, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavsky, I. N. Kushnir, I. F. Umnova, S. S. Kudishina, Т. В. Коротаева, Е. Ю. Логинова, Е. Е. Губарь, Ю. Л. Корсакова, М. В. Седунова, И. Н. Приставский, И. Н. Кушнир, И. Ф. Умнова, С. С. Кудишина

Συνεισφορές: This article has been supported by Sandoz, Статья спонсируется компанией «Сандоз»

Πηγή: Modern Rheumatology Journal; Том 15, № 1 (2021); 27-31 ; Современная ревматология; Том 15, № 1 (2021); 27-31 ; 2310-158X ; 1996-7012

Θεματικοί όροι: метотрексат, minimal disease activity, synthetic disease-modifying antirheumatic drugs, methotrexate, минимальная активность болезни, синтетические базисные противовоспалительные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1096/1053; https://mrj.ima-press.net/mrj/article/view/1096/1061; Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с.; Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011 Dec;70(12):2152-4. doi:10.1136/ard.2011.150938. Epub 2011 Sep 12.; Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favorable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73(2):407-13. doi:10.1136/annrheumdis-2012-201972.; Коротаева ТВ, Логинова ЕЮ, Гетия ТС, Насонов ЕЛ. Результаты применения стратегии «Лечение до достижения цели» у больных ранним псориатическим артритом через 1 год после начала терапии: данные исследования РЕМАРКА. Терапевтический архив. 2018;90(5):22-9.; Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi:10.1136/annrheumdis-2020-217159.; Huynh DH, Boyd TA, Etzel CJ, et al. Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open. 2017 Jan 16;3(1):e000395. doi:10.1136/rmdopen-2016-000395. eCollection 2017.; Логинова EЮ, Коротаева TВ, Губарь ЕЕ и др. Влияние длительности псориатического артрита на достижение ремиссии и минимальной активности болезни на фоне терапии генно-инженерными биологическими препаратами. Данные Общероссийского регистра пациентов с псориатическим артритом. Научно-практическая ревматология. 2020;58(6):695-700.; Логинова ЕЮ, Коротаева ТВ, Корсакова ЮЛ и др. Клинический статус и трудоспособность пациентов, включенных в Общероссийский регистр пациентов с псориатическим артритом. Современная ревматология. 2020;14(3):19-26. doi:10.14412/1996-7012-2020-3-19-26.; Sheane BJ, Thavaneswaran A, Gladman DD, Chandran V. Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. J Rheumatol. 2016 Sep;43(9):1718- 23. doi:10.3899/jrheum.160111. Epub 2016 Jul 15.; Coates LC, Helliwell PS. Methotrexate efficacy in the Tight Control in Psoriatic Arthritis study. J Rheumatol. 2016 Feb;43(2): 356-61. doi:10.3899/jrheum.150614. Epub 2015 Dec 15.; Vena GA, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag. 2018 Jan 9;14:105-16. doi:10.2147/TCRM.S154745. eCollection 2018.; Bianchi G, Caporali R, Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016 Mar;33(3):369-78. doi:10.1007/s12325-016-0295-8. Epub 2016 Feb 4.; Hazlewood GS, Thorne JC, Pope JE, et al. The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. Ann Rheum Dis. 2016 Jun;75(6):1003-8. doi:10.1136/annrheumdis-2014-206504. Epub 2015 May 15.; Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019 Jul; 71(7):1112-24. doi:10.1002/art.40851. Epub 2019 May .

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1096
https://doi.org/10.14412/1996-7012-2021-1-27-31

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis ; Сравнительная эффективность тофацитиниба и адалимумаба у пациентов с псориатическим артритом в реальной клинической практике. Данные Общероссийского регистра пациентов с псориатическим артритом

Συγγραφείς: E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, S. I. Glukhova, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeyeva, E. L. Nasonov, Е. Ю. Логинова, Т. В. Коротаева, Е. Е. Губарь, Ю. Л. Корсакова, С. И. Глухова, Е. А. Василенко, А. А. Василенко, Н. А. Кузнецова, И. М. Патрикеева, Е. Л. Насонов

Πηγή: Modern Rheumatology Journal; Том 15, № 3 (2021); 35–42 ; Современная ревматология; Том 15, № 3 (2021); 35–42 ; 2310-158X ; 1996-7012

Θεματικοί όροι: минимальная активность болезни, tofacitinib, adalimumab, biologic disease-modifying antirheumatic drug, targeted synthetic disease-modifying antirheumatic drug, remission, minimal disease activity, тофацитиниб, адалимумаб, генно-инженерные биологические препараты, таргетные синтетические базисные противовоспалительные препараты, ремиссия

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1145/1104; https://mrj.ima-press.net/mrj/article/view/1145/1109; Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii14-7. doi:10.1136/ard.2004.032482.; Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016 May;68(5):1060-71. doi:10.1002/art.39573. Epub 2016 Mar 23.; Gossec L, Baraliakos X, Kerschbaumer A, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-12. doi:10.1136/annrheumdis-2020-217159.; Murray K, Turk M, Alammari Y, et al. Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther. 2021 Jan 13;23(1):25. doi:10.1186/s13075-020-02380-z.; Haddad A, Gazitt T, Feldhamer I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021 Jan 29;23(1):44. doi:10.1186/s13075-021-02417-x.; Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017 Aug; 47(1):29-37. doi:10.1016/j.semarthrit.2017.02.001. Epub 2017 Feb 8.; Choy E. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2020 Mar 1;59(3):487-94. doi:10.1093/rheumatology/kez664.; Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in Inflammatory and Autoimmune diseases. BioDrugs. 2019 Feb;33(1):15-32. doi:10.1007/s40259-019-00333-w.; Colbert RA, Ward MM. JAK inhibitors taking on psoriatic arthritis. N Engl J Med. 2017 Oct 19;377(16):1582-4. doi:10.1056/NEJMe1709907.; Mease P, Hall S, Fitzgerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017 Oct 19; 377(16):1537-50. doi:10.1056/NEJMoa1615975.; Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525-36. doi:10.1056/NEJMoa1615977.; Nash P, Coates LC, Fleischmann R, et al. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018 Dec; 5(2):567-82. doi:10.1007/s40744-018-0131-5. Epub 2018 Nov 9.; Castro S, Masmitja J, Carlos M. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Adv Ther. 2021 Feb;38(2):868-84. doi:10.1007/s12325-020-01585-7. Epub 2020 Dec 17.; Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-21.; Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017 Dec;77(18): 1987-2001. doi:10.1007/s40265-017-0835-9.; Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018 Sep;14(9):719-30. doi:10.1080/1744666X.2018.1512404.; Логинова ЕЮ, Корсакова ЮЛ, Губарь ЕЕ и др. Эффективность и безопасность то- фацитиниба у больных псориатическим артритом в реальной клинической практике. Научно-практическая ревматология. 2020;58(3):268-75.; Helliwell P, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018 Oct 29;20(1):242. doi:10.1186/s13075-018-1739-0.; Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel- group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020 Oct;79(10):1310-19. doi:10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13.; McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020 May 9;395(10235):1496-505. doi:10.1016/S0140-6736(20)30564-X.; Mease P, Gladman DD, Collier DH, et al. Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis Rheumatol. 2019 Jul;71(7):1112-24. doi:10.1002/art.40851. Epub 2019 May 28.; Lu C, Wallaceb BI, Waljee AK, et al. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis. Semin Arthritis Rheum. 2019 Dec;49(3):381-8. doi:10.1016/j.semarthrit.2019.06.001. Epub 2019 Jun 10.; Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double- blind, placebocontrolled study. Ann Rheum Dis. 2021 Apr 27;annrheumdis-2020-219601. doi:10.1136/annrheumdis-2020-219601. Online ahead of print.; Gubar E, Korotaeva T, Korsakova Y, et al. Effect of tofacitinib treatment on active MRI sacroiliitis and disease activity reduction in psoriatic arthritis patients. Data from clinical practice. Ann Rheum Dis. 2020;79:1162.; www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing; Инструкция по медицинскому применению препарата тофацитиниб (Яквинус) № ЛП-002026-200820.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1145
https://doi.org/10.14412/1996-7012-2021-3-35-42

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib ; Проблемы боли и качества жизни при ревматоидном артрите: фокус на барицитиниб

Συγγραφείς: A. E. Karateev, А. Е. Каратеев

Συνεισφορές: Исследование выполнено в рамках фундаментальной научной темы № 394 0514-2019-0015 «Контроль боли при ревматических заболеваниях: консервативная терапия и хирургические методы коррекции» (АААА-А19-119021190148-3).

Πηγή: Rheumatology Science and Practice; Vol 58, No 4 (2020); 420-427 ; Научно-практическая ревматология; Vol 58, No 4 (2020); 420-427 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: барицитиниб, chronic pain, fatigue, targeted synthetic basic anti-inflammatory drugs, JAK kinase, baricitinib, хроническая боль, утомляемость, таргетные синтетические базисные противовоспалительные препараты, Янус киназа

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2931/2009; Smolen J, Aletaha D, Barton A, et al. Rheumatoid Arthritis. Nat Rev Dis Primers. 2018;4:18001. Published 2018 Feb 8. doi:10.1038/nrdp.2018.1; Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271. https://doi.org/10.14412/1995-4484-2018-263-271; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. Doi:10.14412/1995-4484-2017-409-419; Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med. 2019; 8(7):938. doi:10.3390/jcm8070938; Burmester G, Bijlsma J, Cutolo M, McInnes I. Managing Rheumatic and Musculoskeletal Diseases – Past, Present and Future. Nat Rev Rheumatol. 2017; 13(7):443-448. doi:10.1038/nrrheum.2017.95; Van Tuyl LH, Michaud K. Patient-Reported Outcomes in Rheumatoid Arthritis. Rheum Dis Clin North Am. 2016; 42(2):219-37. doi:10.1016/j.rdc.2016.01.010; Fautrel B, Alten R, Kirkham B, et al. Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018; 38(6):935-947. doi:10.1007/s00296-018-4005-5; Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016; 18(1):114. doi:10.1186/s13075-016-1004-3; Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Curr Osteoporos Rep. 2018;16(5):603-610. doi:10.1007/s11914-018-0473-5; Sharma J, Bhar S, Devi CS. A review on interleukins: The key manipulators in rheumatoid arthritis. Mod Rheumatol. 2017; 27(5):723-746. doi:10.1080/14397595.2016.1266071; Ge C, Holmdahl R. The structure, specificity and function of anti-citrullinated protein antibodies. Nat Rev Rheumatol. 2019;15(8):503-508. doi:10.1038/s41584-019-0244-4; Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing Receptors in Sterile Inflammation and Inflammatory Diseases. Nat Rev Immunol. 2020; 20(2):95-112. doi:10.1038/s41577-019-0215-7; Takeuchi Y, Hirota K, Sakaguch S. Synovial Tissue Inflammation Mediated by Autoimmune T Cells. Front Immunol. 2019;10:1989. doi:10.3389/fimmu.2019.01989.; Nagata S. Apoptosis and Clearance of Apoptotic Cells. Annu Rev Immunol. 2018 Apr 26;36:489-517. doi:10.1146/annurev-immunol-042617-053010; Smith Jr T, Tharakan A, Martin R. Targeting ADAM10 in Cancer and Autoimmunity. Front Immunol. 2020; 11:499. doi:10.3389/fimmu.2020.00499; Deane K, Holers V. The Natural History of Rheumatoid Arthritis. Clin Ther. 2019;41(7):1256-1269. doi:10.1016/j.clinthera.2019.04.028; Uciechowski P, Dempke W. Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020; 98(3):131-137. doi:10.1159/000505099; Crotti C, Agape E, Becciolini A, Biggioggero M, Favalli EG. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. Drugs. 2019; 79(16):1741-1755. doi:10.1007/s40265-019-01192-z; Katz EJ, Gold MS. Inflammatory hyperalgesia: a role for the C-fiber sensory neuron cell body? J Pain. 2006; 7(3):170-8. doi:10.1016/j.jpain.2005.10.003; Chen X, Alessandri-Haber N, Levine JD. Marked attenuation of inflammatory mediator-induced C-fiber sensitization for mechanical and hypotonic stimuli in TRPV4-/- mice. Mol Pain. 2007; 3:31. doi:10.1186/1744-8069-3-31; Lee C-H, Giuliani F. The Role of Inflammation in Depression and Fatigue. Front Immunol. 2019 Jul 19;10:1696. doi:10.3389/fimmu.2019.01696; Kim K-H, Seo H-J, Abdi S., Huh B. All About Pain Pharmacology: What Pain Physicians Should Know. Korean J Pain. 2020;33(2):108-120. doi:10.3344/kjp.2020.33.2.108; Harth M, Nielson WR. Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Rev Clin Immunol. 2019; 15(5):541-552. doi:10.1080/1744666X.2019.1573675; Yang S, Chang M. Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States. Int J Mol Sci. 2019; 20(13):3130. doi:10.3390/ijms20133130; Zhao SS, Duffield SJ, Goodson NJ. The prevalence and impact of comorbid fibromyalgia in inflammatory arthritis. Best Pract Res Clin Rheumatol. 2019;33(3):101423. doi:10.1016/j.berh.2019.06.005; Dougados M, Perrot S. Fibromyalgia and central sensitization in chronic inflammatory joint diseases. Joint Bone Spine. 2017; 84(5):511-513. doi:10.1016/j.jbspin.2017.03.001; Druce KL, Basu N. Predictors of fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 5): v29-v34. doi:10.1093/rheumatology/kez346; Daviu N, Bruchas M, Moghaddam B, Sandi C, Beyeler A. Neurobiological Links Between Stress and Anxiety. Neurobiol Stress. 2019; 11:100191. doi:10.1016/j.ynstr.2019.100191.; Maloley PM, England BR, Sayles H, et al. Post-traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019; 49(2):229-235. doi:10.1016/j.semarthrit.2019.02.002; Tiosano S, Yavne Y, Watad A, et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis.Eur J Clin Invest. 2020 Jun 1:e13268. doi:10.1111/eci.13268; Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018;22(2):216-241. doi:10.1002/ejp.1140; Kaplan C, Minc A, Basu N, Schrepf A. Inflammation and the Central Nervous System in Inflammatory Rheumatic Disease. Curr Rheumatol Rep. 2019;21(12):67. doi:10.1007/s11926-019-0870-5; Kiguchi N, Kobayashi D, Saika F, Matsuzaki S, Kishioka S. Pharmacological Regulation of Neuropathic Pain Driven by Inflammatory Macrophages. Int J Mol Sci. 2017;18(11):2296. doi:10.3390/ijms18112296; Siouti E, Andreakos E. The many facets of macrophages in rheumatoid arthritis. Biochem Pharmacol. 2019;165:152-169. doi:10.1016/j.bcp.2019.03.029; Kothari P, Pestana R, Mesraoua R, et al. IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAKdependent IL-10 expression in macrophages. J Immunol. 2014;192(1):349-57. doi:10.4049/jimmunol.1301906; Salaffi F, Giacobazzi G, Di Carlo M. Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets-A Focus on the JAK-STAT Pathway. Pain Res Manag. 2018;2018:8564215; Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуно-воспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi:10.14412/1995-4484-2019-8-16.; Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33(1):15-32. doi:10.1007/s40259-019-00333-w; Park SJ, Lee JH, Kim HY, et al. Astrocytes, but not microglia, rapidly sense H₂O₂via STAT6 phosphorylation, resulting in cyclooxygenase-2 expression and prostaglandin release. J Immunol. 2012;188(10):5132-5141. doi:10.4049/jimmunol.1101600; Ding CP, Guo YJ, Li HN, et al. Red nucleus interleukin-6 participates in the maintenance of neuropathic pain through JAK/ STAT3 and ERK signaling pathways. Exp Neurol. 2018 Feb;300:212-221. DOI:10.1016/j.expneurol.2017.11.012; Xu Z, Wu H, Zhang H, Bai J, Zhang Z. Interleukins 6/8 and cyclooxygenase-2 Release and Expressions Are Regulated by Oxidative stress-JAK2/STAT3 Signaling Pathway in Human Bronchial Epithelial Cells Exposed to Particulate Matter ≤2.5 μm. J Appl Toxicol. 2020 Mar 24. doi:10.1002/jat.3977; Choy EHS, Miceli-Richard C, González-Gay MA, et al. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol. 2019;37(4):694- 704; Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi:10.1136/annrheumdis-2019-216655; Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научно-практическая ревматология. 2020;58(3):304-316. doi:10.14412/1995-4484-2020-304-316; Pope J, Sawant R, Tundia N, et al. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. Adv Ther. 2020;37(5):2356-2372. doi:10.1007/s12325-020-01303-3; Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376(7):652-662. doi:10.1056/NEJMoa1608345; Keystone EC, Taylor PC, Tanaka Y., et al. Patient-reported Outcomes From a Phase 3 Study of Baricitinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: Secondary Analyses From the RA-BEAM Study. Ann Rheum Dis. 2017;76(11):1853-1861. doi:10.1136/annrheumdis-2017-211259; Taylor PC, Lee YC, Fleischmann R, et al. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial. J Clin Med. 2019;8(6). pii: E831. doi:10.3390/jcm8060831; Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported Outcomes From a Randomised Phase III Study of Baricitinib in Patients With Rheumatoid Arthritis and an Inadequate Response to Biological Agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694-700. doi:10.1136/annrheumdis-2016-209821; Fautrel B, Zhu B, Taylor PC, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1). pii: e001131. doi:10.1136/rmdopen-2019-001131

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2931
https://doi.org/10.47360/1995-4484-2020-420-427

Modern pharmacotherapy of psoriatic arthritis ; Современная фармакотерапия псориатического артрита

Συγγραφείς: Yu. L. Korsakova, T. V. Korotaeva, Ю. Л. Корсакова, Т. В. Коротаева

Πηγή: Rheumatology Science and Practice; Vol 57, No 1 (2019); 75-82 ; Научно-практическая ревматология; Vol 57, No 1 (2019); 75-82 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: генно-инженерные биологические препараты, nonsteroidal anti-inflammatory drugs, glucocorticoids, disease modifying anti-rheumatic drugs, biologicals, нестероидные противовоспалительные препараты, глюкокортикоиды, синтетические и таргетные синтетические базисные противовоспалительные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2677/1804; Scarpa R, Altomare G, Marchesoni A, et al. Psoriatic disease: concepts and implications. J Eur Acad Dermatol Venereol. 2010;24:627-30. doi:10.1111/j.1468-3083.2010.03574.x; Smolen J, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017;0:1-15. doi:10.1136/Ann Rheum Dis-2017-211734; Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489-98. doi:10.1016/S0140-6736(15)00347-5; Gossec L, Smolen, J, Gaujoux-Viala C, et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4-12. doi:10.1136/annrheumdis-2011-200350; Mrowietz U, Domm S. Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol. 2013;27:1022-5. doi:10.1111/j.1468-3083.2012.04656.x; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2018. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2018. 464 p. (In Russ.)].; Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol. 2010;28:S132-7.; Clegg D, Reda D, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veteran's affairs cooperative study. Arthritis Rheum. 1999;42:2325-9. doi:10.1002/1529-0131(199911)42:113.0.CO;2-C; Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol. 1998;25:1957-61.; Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006;212:238-49. doi:10.1159/000091251; Sakellariou G, Sayegh F, Anastasilakis A, et al. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int. 2013;33:2917-20. doi:10.1007/s00296-012-2534-x; Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken). 2013;65:464-70. doi:10.1002/acr.21848; Curtis J, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69:43-7. doi:10.1136/ard.2008.101378; Fraser A, van Kuijk A, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-64. doi:10.1136/ard.2004.024463; Karanikolas G, Koukli E, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol. 2011;38:2466-74. doi:10.3899/jrheum.110242; Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-90. doi:10.1016/j.bcp.2012.01.001; Корсакова ЮЛ, Денисов ЛН. Эффективность и безопасность нового препарата для лечения псориаза и псориатического артрита – апремиласта. Научно-практическая ревматология. 2016;54(5):572-7 [Korsakova YuL, Denisov LN. The efficacy and safety of the new drug apremilast for the treatment of psoriasis and psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):572-7 (In Russ.)]. doi:10.14412/1995-4484-2016-572-577; Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. doi:10.1136/annrheumdis-2013-205056; Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Long-term (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42:479-88. doi:10.3899/jrheum.140647; Mease PJ, Adebajo AO, Gladman DD. Long-term (104-week) safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase 3, randomized, controlled trial and open-label extension [abstract]. Arthritis Rheum. 2014;66 Suppl 10:1564.; Cutolo M, Myerson GR, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724-34. doi:10.3899/jrheum.151376; Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065-73. doi:10.1136/annrheumdis-2015-207963; Wells A, Edwards C, Adebajo AO. Long-term (104-week) safety and efficacy of monotherapy with apremilast in DMARD-naХve patients with psoriatic arthritis: a phase 3, randomized, controlled trial and open-label extension (PALACE 4) [abstract]. Arthritis Rheum. 2014;66 Suppl. 10:L22.; Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537-50. doi:10.1056/NEJMoa1615975; Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377:1525-36. doi:10.1056/NEJMoa1615977; Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-90. doi:10.1016/S0140-6736(00)02530-7; Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72. doi:10.1002/art.20335; Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712-21.; Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147. doi:10.1136/bmj.c147; Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869-76.; Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degreeof clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66:498-505. doi:10.1136/ard.2006.058339; Baranauskaite A, Raffayova H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012;71:541-8. doi:10.1136/ard.2011.152223; Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702-9. doi:10.1136/ard.2008.092767; Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying anti-rheumatic drug therapy. J Rheumatol. 2007;34:1040-50.; Kavanaugh A, McInnes IB, Mease PJ, et al. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a longterm extension of the randomised, placebo-controlled GOREVEAL study. Ann Rheum Dis. 2013;72:1777-85. doi:10.1136/annrheumdis-2012-202035; Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73:1689-94. doi:10.1136/annrheumdis-2013-204902; Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48-55. doi:10.1136/annrheumdis-2013-203696; Van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73:233-7. doi:10.1136/annrheumdis-2013-203697; Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-40. doi:10.1016/S0140-6736(09)60140-9; McInnes IB, Kavanaugh A, Gottlieb AB, et al. on behalf of the PSUMMIT I Study Group: Efficacy and safety of Ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT I trial. Lancet. 2013;382:780-9. doi:10.1016/S0140-6736(13)60594-2; Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000-6. doi:10.1136/annrheumdis-2013-204741; Kavanaugh A, Puig L, Gottlieb AB, et al. Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care Res. 2015;67:1739-49. doi:10.1002/acr.22645; Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional nonbiological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, doubleblind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990-9. doi:10.1136/annrheumdis-2013-204655; Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329-39. doi:10.1056/NEJMoa1412679; Van der Heijde D, Landewe RB, Mease PJ, et al. Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis Rheum. 2016;68:1914-21. doi:10.1002/art.39685; McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2015;386:1137-46. doi:10.1016/S0140-6736(15)61134-5; Saad AA, Ashcroft DM, Watson KD, et al. Persistence with antitumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11:52. doi:10.1186/ar2670; Marchesoni A, Olivieri I, Salvarani C, et al. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exper Rheumatol. 2017;35:991-1010.; Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology. 2014;53(8):1377-85. doi:10.1093/rheumatology/ket409; Sieper J, van der Heijde DM, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009;68(6):784-8. doi:10.1136/ard.2008.101501; Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978-91. doi:10.1136/annrheumdis-2016-210770; Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: a bayesian network meta-analysis. Arch Dermatol. 2012;148:1403-10. doi:10.1001/2013.jamadermatol.238; Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326-38. doi:10.1056/NEJMoa1314258

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2677
https://doi.org/10.14412/1995-4484-2019-75-82

Rheumatoid arthritis: modern principles of diagnosing and treatment (reference review)

Συγγραφείς: Vatutin, N. T., Smyrnova, A. S., Sheveliok, A. N., Taradin, G. G.

Πηγή: Буковинський медичний вісник; Том 19, № 1 (73) (2015): Буковинський медичний вісник; 210-215
Буковинский медицинский вестник; Том 19, № 1 (73) (2015): Буковинский медицинский вестник; 210-215
Bukovinian Medical Herald; Том 19, № 1 (73) (2015): Bukovinian Medical Herald; 210-215

Θεματικοί όροι: ревматоидный артрит, критерии диагноза, цели лечения, «treat to target», базисные противовоспалительные препараты, ревматоїдний артрит, критерії діагнозу, цілі лікування, базисні протизапальні препарати, rheumatoid arthritis, diagnostic criteria, treatment goals, basic anti-inflammatory drugs, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://e-bmv.bsmu.edu.ua/article/download/2413-0737.XIX.1.73.2015.50/105079
http://e-bmv.bsmu.edu.ua/article/download/2413-0737.XIX.1.73.2015.50/105079
http://e-bmv.bsmu.edu.ua/article/view/2413-0737.XIX.1.73.2015.50
http://e-bmv.bsmu.edu.ua/article/view/2413-0737.XIX.1.73.2015.50

FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES ; Факторы, влияющие на эффективность терапии у больных ревматоидным артритом: роль коморбидной психической и соматической патологии

Συγγραφείς: A. A. Abramkin, T. A. Lisitsyna, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, S. I. Glukhova, E. L. Nasonov, А. А. Абрамкин, Т. А. Лисицына, Д. Ю. Вельтищев, О. Ф. Серавина, О. Б. Ковалевская, С. И. Глухова, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 56, No 4 (2018); 439-448 ; Научно-практическая ревматология; Vol 56, No 4 (2018); 439-448 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20184

Θεματικοί όροι: приверженность лечению, mental disorders, disease-modifying antirheumatic drugs, biological agents, efficiency of therapy, predictors, psychopharmacotherapy, therapy adherence, психические расстройства, базисные противовоспалительные препараты, генно-инженерные биологические препараты, эффективность терапии, предикторы, психофармакотерапия

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2589/1732; Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ. 2016;353:i1777. doi:10.1136/bmj.i1777; Donahue KE, Gartlehner G, Jonas DE, et al. Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis. Ann Intern Med. 2008;148(2):124. doi:10.7326/0003-4819-148-2-200801150-00192; Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1113-36. doi:10.1136/annrheumdis-2016-210713; Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;6(6):CD000957. doi:10.1002/14651858.CD000957.pub2; Wijbrandts CA, Tak PP. Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. Mayo Clin Proc. 2017;92(7):1129-43. doi:10.1016/j.mayocp.2017.05.009; Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2015;55(3):kev374.; Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017;13(8):503-10. doi:10.1038/nrrheum.2017.81; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38. doi:10.1016/S0140-6736(16)30173-8; Лисицына ТА, Вельтищев ДЮ. Психические расстройства; у больных ревматическими заболеваниями: диагностика; и лечение. Научно-практическая ревматология. 2015;53(5):512-21 doi:10.14412/1995-4484-2015-512-521; Matcham F, Norton S, Scott DL, et al. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford). 2015;55(2):269-78. doi:10.1093/rheumatology/kev306; Lu M-C, Guo H-R, Lin M-C, et al. Bidirectional associations between rheumatoid arthritis and depression: a nationwide longitudinal study. Sci Rep. 2016;6(February):20647. doi:10.1038/srep20647; Benka J, Nagyova I, Rosenberger J, et al. Social participation in early and established rheumatoid arthritis patients. Disabil Rehabil. 2016;38(12):1172-9. doi:10.3109/09638288.2015.1076071; Feldthusen C, Grimby-Ekman A, Forsblad-D’Elia H, et al. Explanatory factors and predictors of fatigue in persons with rheumatoid arthritis: A longitudinal study. J Rehabil Med. 2016;48(5):469-76. doi:10.2340/16501977-2090; Curtis JR, Bykerk VP, Aassi M, et al. Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic review. J Rheumatol. 2016;43(11):1997-2009. doi:10.3899/jrheum.151212; Markenson JA, Koenig AS, Feng JY, et al. Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis. J Clin Rheumatol. 2013;19(6):317-23. doi:10.1097/RHU.0b013e3182a2164f; Euesden J, Matcham F, Hotopf M, et al. The Relationship Between Mental Health, Disease Severity, and Genetic Risk for Depression in Early Rheumatoid Arthritis. Psychosom Med. 2017;79(6):638-45. doi:10.1097/PSY.0000000000000462; Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2015;67(6):765-75. doi:10.1002/acr.22515; Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. doi:10.1002/art.27584; Насонов ЕЛ. Ревматология. Российские клинические рекомендации. ГЭОТАР-Медиа: Москва, 2017.; Амирджанова ВН, Койлубаева ГН, Горячев ДВ и др. Валида-ция русскоязычной версии Health Assessment Questionnaire (HAQ). Научно-практическая ревматология. 2004;42(2):59-64; Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745-57, vii–viii. doi:10.1016/j.rdc.2009.10.001; Van Gestel AM, Prevoo ML, van’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40. doi:10.1002/art.1780390105; Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. doi:10.1111/j.1600-0447.1983.tb09716.x; Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. doi:10.1111/j.2044-8341.1959.tb00467.x; Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. doi:10.1192/bjp.134.4.382; Лурия АР. Высшие корковые функции человека и их нарушения при локальных поражениях мозга. 2-е изд. Москва: Издательство МГУ; 1962.; Херсонский БГ. Метод пиктограмм в психодиагностике пси-хических заболеваний. Киев: Здоровья; 1988; World Health Organization. The ICD-10 classification of mental and behavioural disorders: Diagnostic criteria for research. 1993: xiii+248p. doi:10.1002/1520-6505(2000)9:53.3.CO;2-P; Зейгарник БВ. Патология мышления. 2-е изд. Москва: Издательство МГУ; 1962; Простые аналогии. Альманах психологических тестов. 3-е изд. Москва: «КСП»; 1995.; Рубинштейн СЯ; Бутенко Г, редактор. Экспериментальные методики патопсихологии и опыт применения их в клинике. Москва: Издательство Института психотерапии; 2010; American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders?: DSM-IV-TR. American Psychiatric Association; 2000.; Герасимов АН. Медицинская статистика: учебное пособие. Москва: Медицинское информационное агентство; 2007; Абрамкин АА. Влияние коморбидных психических расстройств на эффективность терапии у больных ревматоидным артритом. Научно-практическая ревматология. 2016;54(3):339-45 doi:10.14412/1995-4484-2016-339-34; Lee K-E, Choi S-E, Xu H, et al. HAQ score is an independent predictor of sustained remission in patients with rheumatoid arthritis. Rheumatol Int. 2017;37(12):2027-34. doi:10.1007/s00296-017-3833-z; Katchamart W, Johnson S, Lin H-JL, et al. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken). 2010;62(8):1128-43. doi:10.1002/acr.20188; Yu MB, Firek A, Langridge WHR. Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacology. March 12, 2018:1-10. doi:10.1007/s10787-018-0459-z; Romao VC, Vital EM, Fonseca JE, et al. Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? Arthritis Res Ther. 2017;19(1):239. doi:10.1186/s13075-017-1445-3; Hamann P, Holland R, Hyrich K, et al. Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. Arthritis Care Res (Hoboken). 2017;69(6):783-93. doi:10.1002/acr.23016; Kleinert S, Tony HP, Krause A, et al. Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: Data from a German noninterventional observational study. Rheumatol Int. 2012;32(9):2759-67. doi:10.1007/s00296-011-2033-5; Mikuls TR, O’Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004;50(12):3776-82. doi:10.1002/art.20659; Pers Y-M, Fortunet C, Constant E, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford). 2014;53(1):76-84. doi:10.1093/rheumatology/ket301; Albrecht K, Luque Ramos A, Hoffmann F, et al. High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data. Rheumatology (Oxford). 2017;57(2):329-36. doi:10.1007/s00393-017-0294-4; Asai S, Fujibayashi T, Oguchi T, et al. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study. Mod Rheumatol. March 4, 2017:1-6. doi:10.1080/14397595.2017.1332558; Akter N, Qureshi NK, Hoque MA, et al. Extra-Articular Manifestations of Rheumatoid Arthritis & its relation with Treatment Outcome: a tertiary care hospital experience. KYAMC J. 2015;6(1):570-3. doi:10.3329/kyamcj.v6i1.32784; Soliman MM, Hyrich KL, Lunt M, et al. Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. J Rheumatol. 2012;39(2):240-6. doi:10.3899/jrheum.110610; McWilliams DF, Ferguson E, Young A, et al. Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data. Arthritis Res Ther. 2016;18(1):295. doi:10.1186/s13075-016-1186-8; Scheiman-Elazary A, Duan L, Shourt C, et al. The rate of adherence to antiarthritis medications and associated factors among patients with rheumatoid arthritis: A systematic literature review and metaanalysis. J Rheumatol. 2016;43(3):512-23. doi:10.3899/jrheum.141371; Joshi K, Lin J, Lingohr-Smith M, et al. Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United States. J Clin Psychopharmacol. 2016;36(5):429-35.; Gray R, Bressington D, Ivanecka A, et al. Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis. BMC Psychiatry. 2016;16:90. doi:10.1186/s12888-016-0801-1; Jain A, Bhadauria D. Evaluation of efficacy of fluoxetine in the management of major depression and arthritis in patients of Rheumatoid Arthritis. Ind J Rheumatol. 2013;8(4):165-9. doi:10.1016/j.injr.2013.08.001; Kekow J, Moots R, Khandker R, et al. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford). 2011;50(2):401-9. doi:10.1093/rheumatology/keq327; Karpouzas GA, Draper T, Moran R, et al. Trends in functional disability and determinants of clinically meaningful change over time in Hispanics with Rheumatoid arthritis in the United States. Arthritis Care Res. 2016;69(2):294-8. doi:10.1002/acr.22924; Fiest KM, Hitchon CA, Bernstein CN, et al. Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. J Clin Rheumatol. 2017;00(00):1. doi:10.1097/RHU.0000000000000489

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2589
https://doi.org/10.14412/1995-4484-2018-439-448

THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS ; Влияние адекватной психофармакотерапии на эффективность лечения больных ревматоидным артритом

Συγγραφείς: A. A. Abramkin, T. A. Lisitsyna, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, E. L. Nasonov, А. А. Абрамкин, Т. А. Лисицына, Д. Ю. Вельтищев, О. Ф. Серавина, О. Б. Ковалевская, Е. Л. Насонов

Πηγή: Rheumatology Science and Practice; Vol 56, No 2 (2018); 173-183 ; Научно-практическая ревматология; Vol 56, No 2 (2018); 173-183 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20182

Θεματικοί όροι: приверженность лечению, mental disorders, disease-modifying antirheumatic drugs, biological agents, remission, efficiency of therapy, psychopharmacotherapy, therapy adherence, психические расстройства, базисные противовоспалительные препараты, генно-инженерные биологические препараты, эффективность терапии, ремиссия, психофармакотерапия

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2522/1677; Nikiphorou E, Buch MH, Hyrich K. Biologics registers in RA: methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017 Aug;13(8):503-10. doi:10.1038/nrrheum.2017.81; Chatzidionysiou K, Emamikia S, Nam J, et al. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1102-7. doi:10.1136/annrheumdis-2016-210711; Nam JL, Takase-Minegishi K, Ramiro S, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun;76(6):1113-36. doi:10.1136/annrheumdis-2016-210713; Wijbrandts CA. Prediction of Response to Targeted Treatment in Rheumatoid Arthritis. Mayo Clin Proc. July 2017;92(7):1129-43. doi:10.1016/j.mayocp.2017.05.00; Kekow J, Moots R, Khandker R, et al. Improvements in patients reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate to severe active early rheumatoid arthritis. Rheumatology. 2011;50:401-9. doi:10.1093/rheumatology/keq327; Cabrera-Marroquin R, Contreras-Yanez I, Alcocer-Castillejos N, Pascual-Ramos V. Major depressive episodes are associated with poor concordance with therapy in rheumatoid arthritis patients: the impact on disease outcomes. Clin Exp Rheumatol. 2014 NovDec;32(6):904-13.; Matcham F, Norton S, Scott DL, et al. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford). 2016 Feb;55(2):268-78. doi:10.1093/rheumatology/kev306; Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: A systematic review. Rheumatology (Oxford). 2013;52(10):1785-94. doi:10.1093/rheumatology/kes356; Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and metaanalysis. Rheumatology (Oxford). 2013;52:2136-48. doi:10.1093/rheumatology/ket169; Watad A, Bragazzi NL, Adawi M, et al. Anxiety disorder among rheumatoid arthritis patients: Insights from reallife data. J Affect Disord. 2017;213:30-4. doi:10.1016/j.jad.2017.02.007; Hanly JG, Omisade A, Su Li, et al. Cognitive function in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis assessed by computerized neuropsychological tests. Arthritis Rheum. 2010;62(5):1478-86. doi:10.1002/art.27404; Meade T, Manolios N, Cumming SR, et al. Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken). 2017 Mar 28. doi:10.1002/acr.23243; Fiest KM, Hitchon CA, Bernstein ChN, et al. Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases. J Clin Rheumatol. 2017;23(8):425-34. doi:10.1097/RHU.0000000000000489; Leblanc-Trudeau C, Dobkin PL, Carrier N, et al. Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis. Rheumatology (Oxford). 2015 Dec;54(12):2205-14. doi:10.1093/rheumatology/kev272; Katon WJ, Lin EH, Von Korff M, et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010 Dec 30;363(27):2611-20. doi:10.1056/NEJMoa1003955; Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. doi:10.1002/art.1780310302; Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 464 с.; Amirdzhanova VN, Kojlubaeva GM, Goryachev DV, et al. Validation of the Russian version HAQ. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2004;42(2):59-65 (In Russ.).; Van Gestel AM, Prevoo ML, van’t Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum. 1996;39:34-40. doi:10.1002/art.1780390105; Felson DT, Smolen JS, Wells G, et al.; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-86. doi:10.1002/art.30129; Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-70. doi:10.1111/j.1600-0447.1983.tb09716.x; Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. doi:10.1111/j.2044-8341.1959.tb00467.x; Montgomery SA, Asberg MA. New depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9. doi:10.1192/bjp.134.4.382; Luriya AP. Vysshie korkovye funktsii cheloveka [Higher cortical functions of man]. Moscow; 1962 (In Russ).; Khersonskii BG. Metod piktogramm v psikhodiagnostike psikhicheskikh zabolevanii [The method of pictograms in the psychodiagnosis of mental illness]. Kiev; 1988. (In Russ).; ICD-10 classification of mental and behavioral disorders. Diagnostic criteria for research. 10th revision (ICD-10). Geneva: World Health Organization; 1983. doi:10.1176/appi.books.9780890423349.6544; Zeigarnik BV. Patologiya myshleniya [Pathology of thinking]. Moscow; 1962 (In Russ).; Prostye analogii. Al'manakh psikhologicheskikh testov [Simple analogies. Almanac of psychological tests]. Moscow; 1995. P. 127–30 (In Russ).; Rubinshtein SYa. Eksperimental'nye metodiki patopsikhologii i opyt primeneniya ikh v klinike [Experimental methods of pathopsychology and experience of their application in the clinical practice]. Moscow; 2004. (In Russ).; American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (text revision). Washington, DC: American Psychiatric Association; 2000.; Abramkin AA, Lisitsyna TA, Veltishchev DYu, et al. Effects of synthetic disease-modifying antirheumatic drugs, biological agents, and psychopharmacotherapy on the mental disorders in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):393-402 (In Russ.). doi:10.14412/1995-4484-2017-393-402; Fusama M, Miura Y, Yukioka K, et al. Psychological state is related to the remission of the Boolean-based definition of patient global assessment in patients with rheumatoid arthritis. Mod Rheumatol. 2015 Sep;25(5):679-82. doi:10.3109/14397595.2015.1008955; Depression Guideline Panel. Depression in primary care: volume 2. Treatment of major depression. Clinical practice guideline, number 5. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service; 1993.; Richards BL, Whittle SL, van der Heijde DM, Buchbinder R. The efficacy and safety of antidepressants in inflammatory arthritis: A Cochrane systematic review. J Rheumatol. 2012 Sep;90 Suppl:21-7. doi:10.3899/jrheum.120338; Lisitsyna TA, Vel’tishchev DYu, Krasnov VN, Nasonov EL. Clinical and pathogenetic associations between immuno-inflammatory rheumatic diseases and mental disorders. Klinicheskaya Meditsina. 2014;(1):12-21 (In Russ.).; Lisitsyna TA, Vel'tishhev DJ, Seravina OF, et al. Proinflammatory cytokines and depression in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):261-6 (In Russ.). doi:10.14412/1995-4484-2013-14986; Sacre S, Medghalchi M, Gregory B, et al. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors. Arthritis Rheum. 2010 Mar;62(3):683-93. doi:10.1002/art.27304; Lisitsyna TA, Vel'tishhev DYu, Gerasimov AN, et al. Factors affecting the perception of pain in rheumatoid arthritis. Klinicheskaja Medicina. 2013;(3):54-61 (In Russ).

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2522
https://doi.org/10.14412/1995-4484-2018-173-183

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION ; Стратегия снижения дозы и отмены генно-инженерных биологических препаратов при ревматоидном артрите в стадии ремиссии

Συγγραφείς: M. A. Kotovskaya, N. Yu. Nikishina, Yu. A. Olyunin, М. А. Котовская, Н. Ю. Никишина, Ю. А. Олюнин

Πηγή: Rheumatology Science and Practice; Vol 56, No 1 (2018); 99-106 ; Научно-практическая ревматология; Vol 56, No 1 (2018); 99-106 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20181

Θεματικοί όροι: ремиссия, biological agents, disease-modifying antirheumatic drugs, treatment, remission, генно-инженерные биологические препараты, базисные противовоспалительные препараты, лечение

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2506/1664; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: российские и международные рекомендации. Научнопрактическая ревматология. 2016;54(5):557-71 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: Russian and International guidelines. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):557-71 (In Russ.)]. doi:10.14412/1995-4484-2016557-571; Каратеев ДЕ, Лучихина ЕЛ, Демидова НВ и др. Применение подкожной формы метотрексата для лечения больных активным ревматоидным артритом (исследование РЕМАРКА). Научно-практическая ревматология. 2016;54(2):138-44 [Karateev DE, Luchikhina EL, Demidova NV, et al. Use of subcutaneous methotrexate for the treatment of patients with active rheumatoid arthritis: The REMARCA trial. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):138-44 (In Russ.)]. doi:10.14412/19954484-2016-138-144; Борисова МА, Лукина ГВ, Сигидин ЯА и др. Сравнительная оценка эффективности и безопасности абатацепта у пациентов с разной длительностью ревматоидного артрита. Научно-практическая ревматология. 2016;54(6):667-73 [Borisova MA, Lukina GV, Sigidin YaA, et al. Comparative evaluation of the efficacy and safety of abatacept in patients with different duration of rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):667-73 (In Russ.)]. doi:10.14412/1995-4484-2016667-673; Каратеев ДЕ, Лучихина ЕЛ, Демидова НВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА): результаты лечения 130 больных в течение 12 месяцев. Научно-практическая ревматология. 2014;52(6):607-14 [Karateev DE, Luchikhina EL, Demidova NV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA trial): Results of 12-month treatment in 130 patients. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(6):607-14. doi:10.14412/1995-4484-2014607-614; Van Herwaarden N, den Broeder A, Jacobs W, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2014;9:CD010455. doi:10.1002/14651858.CD010455.pub2; Bongartz T, Sutton A, Sweeting M, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85. doi:10.1001/jama.295.19.2275; Fautrel B, Verstappen S, Boonen A. Economic consequences and potential benefits. Best Pract Res Clin Rheumatol. 2011;25:607-24. doi:10.1016/j.berh.2011.10.001; Den Broeder A, van der Maas A, van den Bemt B. Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology (Oxford). 2010;49:1801-3. doi:10.1093/rheumatology/keq060; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.].; Van Vollenhoven R. How to dose infliximabin rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis. 2009;68:1237-9. doi:10.1136/ard.2009.111682; Smolen J, Breedveld F, Burmester G, et al. Treating rheumatoid arthritis to target:2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3-15. doi:10.1136/annrheumdis-2015-207524; Smolen J. 2016 Update of EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. EULAR Meeting. 2016 [cited 2016 Jul 31. Available from: http://www.eular.org/clinical_affairs_initiatives.cfm].; Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. J Bone Spine. 2009;76:350-5. doi:10.1016/j.jbspin.2008.11.009; Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69:1286-91. doi:10.1136/ard.2009.121491; Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74:389-95. doi:10.1136/annrheumdis-2013-204016; Chatzidionysiou K, Turesson C, Teleman A, et al. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open. 2016;2:e000133. doi:10.1136/rmdopen-2015-000133; Smolen J, Emery P, Ferraccioli G, et al. Cetrolizumabpegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomized, placebo-controlled trial. Ann Rheum Dis. 2015;74:843-50. doi:10.1136/annrheumdis-2013204632; Yoshida K, Kishimoto M, Radner H, et al. Low rates of biologicfree clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. Rheumatology (Oxford). 2016;55:286-90. doi:10.1093/rheumatology/kev329; Smolen J, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etenercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381:918-29. doi:10.1016/S0140-6736(12)61811-X; Van Vollenhoven R, Ostergaard M, Leirisalo-Repo M, et al. Full dose, reduced dose or discontinuation of etanerceptin rheumatoid arthritis. Ann Rheum Dis. 2016;75:52-8. doi:10.1136/annrheumdis-2014-205726; Van der Maas A, Kievit W, van den Bemt BJF, et al. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012;71:1849-54. doi:10.1136/annrheumdis-2011-200945; Fautrel B, Pham T, Alfaiate T, et al. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission : results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid Arthritis Study). Ann Rheum Dis. 2016;75:59-67. doi:10.1136/annrheumdis-2014-206696; Van Herwaarden N, van der Maas A, Minten M, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis:apen label, randomized controlled, non-inferiority trial. BMJ. 2015;350:h1389. doi:10.1136/bmj.h1389; Takeuchi T, Matsubara T, Ohta S, et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatoilogy (Oxford). 2015;54:683-91. doi:10.1093/rheumatology/keu338; Aguilar-Lozano L, Castillo-Ortiz J, Vargas-Serafin C, et al. Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis. J Rheumatol. 2013;40:1069-73. doi:10.3899/jrheum.121427; Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free Remission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol Jpn Rheum Assoc. 2014;24:17-25. doi:10.3109/14397595.2013.854079; Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomized controlled strategy trial in rheumatoid arthritis (ACTRAY). Ann Rheum Dis. 2013;72:43-50. doi:10.1136/annrheumdis2011-201282; Huizinga TWJ, Cohaghan P, Martin-Mola E, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74:35-43. doi:10.1136/annrheumdis-2014-205752; Moghadam M, Vonkeman H, Ten Klooster P, et al. Stopping tumor necrosis factor-inhibitors in patients with established rheumatoid arthritis in remission or stable low disease activity: a pragmatic randomized multicenter open-label controlled trial. Arthritis Rheum. 2016;68:1810-7. doi:10.1002/art.39626; Haschka J, Englbrecht M, Hueber A, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stoppering antirheumatic therapy: interim results from prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75:4551. doi:10.1136/annrheumdis-2014-206439; Лучихина ЕЛ, Каратеев ДЕ, Демидова НВ и др. Возможность сохранения результатов лечения у больных активным ревматоидным артритом после снижения дозы и/или отмены генно-инженерных биологических препаратов (РЕМАРКА). Современная ревматология. 2016;10(4):16-20 [Luchikhina EL, Karateev DE, Demidova NV, et al. Possibilities for preserving the results of treatment in patients with active rheumatoid arthritis after dose reduction and/or discontinuation of biological agents: A REMARCA study. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):16-20 (In Russ.)]. doi:10.14412/1996-7012-2016-4-16-20; Felson D, Smolen J, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-86. doi:10.1002/art.30129; Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8:e60635. doi:10.1371/journal.pone.0060635; Crescendo Biosciences I. Vectra DA: Overview for Health Care Professionals. 2016; 2016 [Internet. Available from: http://www.vectrada.com/health-care-professionals/].; Rech J, Hueber A, Finzel S, et al. Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment. Ann Rheum Dis. 2016;75:1637-44. doi:10.1136/annrheumdis-2015207900; Lamers-Karnebeek F, Moghadam M, Vonkeman H. Multi-biomarker disease activity score as a predictor of flare in patients with rheumatoid arthritis who stop TNF-alpha-inhibitor therapy [Internet]. ACR Meeting Abstracts. [cited 2016 Jul 17]. Available from: http://acrabstracts.org/abstract/multi-biomarker-diseaseactivity-score-as-a-predictor-of-flare-in-patients-with-rheumatoid-arthritis-who-stop-tnf-alpha-inhibitor-therapy/; Bouman C, van der Maas A, van Herwaarden N, et al. The multibiomarkers disease activity score in a TNF inhibitor tapering study in rheumatoid arthritis patirnts: predictive value for successful tapering, flaring and radiographic progression [Internet]. ACR Meeting Abstracts. [cited 2016 Jul 17]. Available from: http://acrabstracts.org/abstract/the-multi-biomarker-diseaseactivity-score-in-a-tnf-inhibitor-tapering-study-in-rheumatoidarthritis-patients-predictive-value-for-successful-tapering-flaringand-radiographic-progression/; Новиков AA, Александрова ЕН, Герасимов АН и др. Применение многопараметрического анализа лабораторных биомаркеров для оценки активности ревматоидного артрита. Научно-практическая ревматология. 2015;53(6):591-5 [Novikov AA, Aleksandrova EN, Gerasimov AN, et al. Use of multiparameter analysis of laboratory biomarkers to assess rheumatoid arthritis activity. NauchnoPrakticheskaya Revmatologiya=Rheumatology Science and Practice. 2015;53(6):591-5 (In Russ.)]. doi:10.14412/1995-44842015-591-595; Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, et al. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014;53:2110-8. doi:10.1093/rheumatology/keu217; Zufferey P, Riek M, Tamborrini G, et al. Ultrasound residual synovitis has an impact on the time to relase in RA Patients Considered in Clinical Remission: A real life study of 211 Patients [Internet]. ACR Meeting Abstracts. [cited 2016 Jul 17]. Available from: http://acrabstracts/org/abstract/ultrasound-residual-synovitis-has-an-impact-on-the-time-to-relapse-in-ra-patients-considered-in-clinical-remission-a-real-life-study-of-211-patients/; Szkudlarek M, Court-Payen M, Jacobsen S, et al. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003;48:955-62. doi:10.1002/art.10877; D'Agostino M, Conagham P, Naredo E, et al. The OMERACT Ultrasound Task Force – advances and priorities. J Rheumatol. 2009;36:1829-32. doi:10.3899/jrheum.090354; Iagnocco A, Naredo E, Wakefield R, et al. Responsiveness in rheumatoid arthritis. A report from OMERACT 11 ultrasound workshop. J Rheumatol. 2014;41:379-82. doi:10.3899/jrheum.131084; Alcalde M, D'Agostino M, Bruyn G, et al. A systematic literature review of US definitions, scoring systems and validity according to the OMERACT filter for tendon lesion in RA and other inflammatory joint diseases. Rheumatology (Oxford). 2012;51:1246-60. doi:10.1093/rheumatology/kes018; Gandjbakhch F, Foltz V, Mallet A, et al. Bone marrow oedema predicts structural progression in a 1-year follow-up of 85 patients with RA in remission or with low-field MRI. Ann Rheum Dis. 2011;70:2159-62. doi:10.1136/ard.2010.149377; Gajoux-Viala C, Gossec L, Cantarel A, et al. [Recommandations de la Societe francaise de rhumatologie pour la prise en charge de la polyarthrite rhumatoide]. Rev Rhum. 2014;81:303-12 (In Franc.). doi:10.1016/j.rhum.2014.04.009; Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ. и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117-25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). NauchnoPrakticheskaya Revmatologiya=Rheumatology Science and Practice. 2013;51(2):117-25 (In Russ.)]. doi:10.14412/1995-4484-2013-637; Takeuchi T, Matsubara T, Ohta S, et al. SAT0100 Abatacept biologic-free remission study in established rheumatoid arthritis patients orion study. Ann Rheum Dis. 2013;72 Suppl 3:[A613].; Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52:53-61. doi:10.1093/rheumatology/kes305

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/2506
https://doi.org/10.14412/1995-4484-2018-99-106